

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055551
Article Type:	Original research
Date Submitted by the Author:	15-Jul-2021
Complete List of Authors:	Osanlou, Rostam; University of Liverpool, Department of Pharmacology and Therapeutics; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Pharmacology and Therapeutics Walker, Lauren; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics Hughes, Dyfrig; Bangor University, Centre for Health Economics and Medicines Evaluation Burnside, Girvan; University of Liverpool, Department of Biostatistics Pirmohamed, Munir; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics
Keywords:	Adverse events < THERAPEUTICS, CLINICAL PHARMACOLOGY, HEALTH ECONOMICS, INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Rostam Osanlou<sup>1,2</sup>, Lauren Walker<sup>1,2</sup>, Dyfrig Hughes<sup>3</sup>, Girvan Burnside<sup>4</sup>, Munir Pirmohamed<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE

<sup>2</sup>Liverpool University Hospital Foundation NHS Trust, Prescot Street, Liverpool, L7 8XP

<sup>3</sup>Centre for health economics and medicines evaluation, University of Bangor, College Road, Bangor LL57 2DG

<sup>4</sup>Department of Biostatistics, University of Liverpool, Liverpool L69 3GE

Author for correspondence:

Prof M Pirmohamed  
Institute of Systems, Molecular and Integrative Biology (ISMIB)  
University of Liverpool  
Block A: Waterhouse Building  
1-5 Brownlow Street  
Liverpool L69 3GL  
[munirp@liverpool.ac.uk](mailto:munirp@liverpool.ac.uk)

**Word count:** 2,856

**Keywords:** Adverse drug reaction, ADR, Multimorbidity, Polypharmacy

## ABSTRACT

**Objective** To ascertain the burden of adverse drug reactions (ADRs), polypharmacy and multimorbidity through a prospective analysis of all medical admissions to a large University teaching hospital over a one-month period.

**Design** Prospective observational study.

**Setting** Liverpool University Hospital Foundation NHS Trust, England.

**Participants** All medical admissions with greater than 24-hour stay over a one-month period.

**Main outcome measures** Prevalence of admissions due to an ADR and associated mortality. Prevalence and association of multimorbidity and polypharmacy with ADRs. Estimated local financial cost of admissions where ADR was a contributing or main reason for admission with projected costs for NHS in England.

**Results** There were 218 identified patient admissions with an ADR giving a prevalence of 18.4%. The majority of these (90.4%) were ADRs that directly resulted in or contributed to admission. ADRs thus accounted for 16.5% of total admissions. Those with an ADR were on average taking more medicines (10.5 vs 7.8  $p<0.01$ ) and had more co-morbidities than those without an ADR (6.1 vs 5.2,  $p<0.01$ ). Drugs most commonly implicated were diuretics, steroid inhalers, anticoagulants & antiplatelets, proton pump inhibitors, chemotherapeutic agents and antihypertensives. 40.4% of ADRs were classified avoidable or possibly avoidable. The mortality rate due to an ADR was 0.34%. The average length of stay for those with an ADR was 6 days. Direct one month cost to the Trust from ADR admissions was £490,716. Extrapolated nationally the projected annual cost to the NHS in England is 2.21bn.

**Conclusion** The local prevalence of admission and mortality from ADRs are higher than previously reported. Important factors that could be contributing to this include polypharmacy and multimorbidity. ADRs place a significant burden on patients and healthcare services with associated financial implications. Reducing inappropriate polypharmacy should be a major aim for preventing ADRs.

**Strengths and limitations of this study:**

- Over 1000 medical admissions were individually reviewed by specialists in clinical pharmacology and general internal medicine in this prospective analysis of adverse drug reactions.
- Standardised criteria, as listed in methods, were used to identify and classify ADRs. This improves the objectivity and reproducibility of the analysis.
- Extrapolating the cost analysis nationally based on medical admissions locally may be unreliable due to differences including local population and services.
- This study does not take into account how commonly each medicine that caused an ADR is prescribed in the local community.

## INTRODUCTION

Improved living conditions, and better access to and quality of medical care, has led to increased life expectancy and the associated accumulation of Long Term Conditions (LTC) <sup>(1)</sup>. According to a report by the Academy of Medical Sciences, multimorbidity is a growing issue globally, particularly in more economically developed countries where it is now considered the norm not the exception <sup>(2)</sup>. Age is the single biggest risk factor for LTCs such as cancer, cardiovascular disease and neurodegeneration in developed countries. An ageing population is therefore at increased risk of polypharmacy <sup>(3)</sup>. Care for people with multiple LTCs is often stretched across various single-organ specialists leading to siloed specialty prescribing and increasingly complex medication regimens.

Polypharmacy is the concurrent use of multiple medications by an individual. Numerical definitions vary but it is most commonly defined as taking 5 or more regular medications <sup>(4)</sup>. The Wessex Academic Health Science Network have developed a set of prescribing comparators to better understand both the numerical and risk-related factors involved in the variation of prescribing of multiple medicines <sup>(5)</sup>. Appropriate polypharmacy can improve health outcomes in multimorbidity, the co-occurrence of two or more long term conditions. In contrast, potentially inappropriate polypharmacy, wherein the risk of harms from individual medicines may outweigh their benefit in the context of the prescription as a whole, is associated with poor adherence and an increased risk of adverse-drug reactions (ADRs) and interactions <sup>(6)</sup>. ADRs are an important cause of morbidity and mortality, with significant health implications and associated economic burden. Landmark studies in the USA in 1998 <sup>(7)</sup> and the UK in 2004 <sup>(8)</sup> found ADRs to be related to 6.7% and 6.5% of hospital admissions, respectively. More recent systematic reviews have reported figures ranging from 3.6% <sup>(9)</sup> to 15.6% <sup>(10)</sup>. Potential reasons for variation in findings include the heterogeneity of methodologies and populations studied.

Addressing avoidable ADRs due to inappropriate prescribing is important to reduce the burden on patients and healthcare systems. There are few adult observational studies of admission ADRs in the United Kingdom that are not focused on a specific populations or drug reactions. To our knowledge there are only 3 in the last 20 years <sup>(8,11,12)</sup>. The aim of this study was to determine the current impact of ADRs on medical admissions, their association with multimorbidity and polypharmacy, and quantify the economic impact on the National Health Service (NHS). The population studied is broadly geographically comparable to that of Pirmohamed et al 2004 <sup>(8)</sup>.

## METHODS

Study data was collected for one month in the city centre site of the Liverpool University Hospital Foundation NHS Trust, a large teaching hospital in Merseyside, England. Approval for data collection was obtained through governance processes within the Trust. All patients referred via the medical assessment unit that were admitted for >24 hours were included. These were mostly via the emergency department but also included primary care referrals and admissions from outpatient clinics. Patients admitted via medicine but transferred to other centres for emergency treatment (such as primary coronary intervention) within 24 hours were included, as their expected inpatient stay would be >24 hours. Information including e-notes, community drug prescriptions and investigations were reviewed to determine if an ADR occurred. An ADR was defined using the Edwards and Aronson criteria<sup>(13)</sup>. This does not include any type of drug overdose or relapse due to noncompliance. Cases were then defined as either the primary cause of admission, contributing factor or a co-incidental finding and assessed against the following criteria:

- Classification of the reaction as per Rawlins and Thompson<sup>(14)</sup>
- Causality as per the Liverpool causality assessment tool (LCAT)<sup>(15)</sup>
- Severity as per the adapted Hartwig severity scale (AHSS)<sup>(16)</sup>
- Interactions as per the drug interaction probability scale (DIPS)<sup>(17)</sup>
- Avoidability as per the Liverpool ADR avoidability assessment tool (LAAT)<sup>(18)</sup>

Factors that suggested an ADR include if it was consistent with the known adverse effect profile of the drug as per the British National Formulary<sup>(19)</sup>, if there was a temporal relationship, and if alternate causes were excluded with history and investigation. Community drug prescription were verified and reviewed with patient electronic notes. This data was available for all admitted patients. If it was documented in the notes that a patient was not taking a medicine listed on their prescription this was not included in our analysis.

Identification of ADRs and subsequent assessment of the above criteria was completed by authors RO and LW. Where consensus was not reached it was assessed by third reviewer MP. Of the 258 patient episodes with possible identified ADRs, there was initial agreement on 236 (91%). For the remainder consensus was obtained following joint review with MP.

Patient Level Information and Costing System (PLICS) data reporting healthcare resource group and hospital costs were obtained from the Liverpool University Hospitals NHS Foundation Trust finance office. Total costs were summed for episodes of admitted care resulting from ADRs (a), and for all other admissions (where ADR was a contributory factor, coincidental, or unrelated; (b)). In order to



1  
2  
3 extrapolate costs, totals for non-elective short and long stay, and regular day or night admissions, for  
4 NHS England (c), were obtained for 2018-19 <sup>(20)</sup>. Nationally projected costs were estimated as  
5 (a.c)/(a+b).  
6  
7

## 8 9 **STATISTICAL ANALYSIS**

10  
11 Statistical analysis was performed using the SAS software (Version 9.4, SAS Institute, Cary, NC, USA).  
12 The results are presented either as means and standard deviations or frequencies and percentages.  
13 Associations between patient characteristics and admission type (ADR/Non-ADR) were investigated  
14 using univariable and multivariable logistic regression, with associations presented as odds ratios  
15 (OR) with 95% confidence intervals. The multivariable model used backwards selection with a  
16 probability of exclusion of 0.1. A P value < 0.05 was regarded as statistically significant.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

There were 1,187 admissions with 218 patients with an ADR (18.4%). As some of those had multiple ADRs 235 were identified in total.

### Characteristics of adverse drug reactions

145 (66.5%) of the ADRs were the primary cause of admission, with 51 (23.4%) contributing to admission, and 22 (10.1%) co-incidental findings that alone would not have required hospital stay. Thus, ADRs directly caused or contributed to 16.6% of all admissions. Using the Liverpool causality assessment tool<sup>(15)</sup> 45 (20.6%) were graded as definite, 79 (36.2%) as probable, and 94 (43.1%) as possible ADRs. 40 (18.4%) were graded as avoidable and 46 (21.1%) as possibly avoidable using LAAT criteria<sup>(18)</sup>. 64 (29.4%) of ADRs were possibly or probably cause by a drug-drug interaction as per DIPS<sup>(17)</sup>. 188 (86.2%) were Type A reactions as defined by Rawlins and Thompson<sup>(14)</sup> and 30 (13.8%) Type B. 164 (75.2%) of the ADRs were documented as recognised or acted on by the admitting medical team. The main drugs implicated in ADRs are listed in table 1. There were 4 ADRs (1.8%) that directly resulted in death and a further 5 that were implicated or a contributing factor to death (2.3%) (table 2). The mortality rate directly from ADRs, from all admissions, was therefore 0.42%. Median length of stay of patients with an ADR was 6 days.

### Comparison of patients with and without adverse drug reactions

Table 3 shows descriptive statistics of patients with and without ADRs. Logistic regression results are presented in Table 4. Patients with ADRs were older than those without (mean age 73.2 (14.5) vs 66.7 (19.2), OR 1.02 (1.01, 1.03)) and were taking more medicines (mean 10.5 (4.6) vs 7.8 (5.1), OR 1.11 (1.07, 1.14)), with polypharmacy present in 91%, compared to 73% in the non-ADR group. They had more comorbidities (mean 6.1 (3.0) vs 5.2 (3.3), OR 1.08 (1.04, 1.13)), although this variable was not included in the multivariable model (possibly due to its correlation with number of medicines). Those with ADRs were more likely to have liver impairment (6.9% vs 2.8%, OR 2.58 (1.35, 4.93)) and renal impairment (11.0% vs 6.8%, OR 1.69 (1.04, 2.78)).

HRG costs were available for 214 (98.2%) patients in the ADR group, and 950 (98.0%) patients in the non-ADR group. Mean costs per episode of care were £2,293 (95% CI 1918, 2668) and £2,131 (95% CI 1899, 2364), respectively. The total costs of admissions resulting from ADR were £309,207, representing 12.3% of the costs of the whole cohort over the 1-month sampling frame. Admissions where ADR was a contributory factor cost £138,762 (5.5%); and where ADR was coincidental, the cost was £42,747 (1.7%). The total costs of non-elective short and long stays, and regular day or

1  
2  
3 night admissions across all NHS trusts and NHS foundation trusts in England was £17.98 bn in 2018-  
4  
5 19, of which we estimate £2.21 bn were due to admissions resulting from ADRs.

## 6 7 **DISCUSSION**

8  
9 This study found ADRs in 18.4% of hospital admissions. In 16.6% of admissions, it was the primary  
10 cause or a contributing cause suggesting ADRs have a significant burden on hospital admissions. This  
11 is over twice as high as the 6.5% found in Pirmohamed 2004 <sup>(8)</sup> which consisted of broadly the same  
12 geographical area. Most commonly implicated medicines included diuretics, steroid based inhalers,  
13 anticoagulants, proton pump inhibitors, antiplatelets, chemotherapy agents, anti-hypertensives,  
14 opiates and antidepressants/antipsychotics (Table 1). It is important to consider this study does not  
15 reflect how often each of these medicines are prescribed in the community. Some of the medicines  
16 implicated with the highest number of ADRs and deaths may be a reflection of how commonly they  
17 are prescribed. Furthermore, the use of these medicines also provides clinical benefits that reduce  
18 morbidity, mortality and need for hospital admissions, and this is not taken into account by our data.  
19 Direct mortality from ADRs was 0.42% which is also an increase from Pirmohamed 2004 (0.15%) <sup>(8)</sup>  
20 and twice as high as a recent meta-analysis <sup>(21)</sup>.

21  
22 Approximately, 40% of ADRs were classified as avoidable or possibly avoidable. This is consistent  
23 with previous studies which found significant proportions of ADRs that lead to hospital admissions  
24 are potentially avoidable <sup>(22)</sup>. Given this, future efforts should be targeted at reducing these  
25 preventable admissions. Key strategies that can mitigate for ADRs include stratifying patients by  
26 susceptibility prior to medication initiation using key information such as co-morbidities,  
27 concomitant medications and renal and hepatic function. Where available and appropriate,  
28 pharmacogenomic testing can also be used to identify those at high risk of an ADR to guide  
29 medication choice, or optimal dose. Following initiation, management plans such as appropriate  
30 blood test monitoring and scheduled clinical review for ongoing indication can also reduce the risk of  
31 an ADR<sup>(23)</sup>. 29.4% of ADRs were possibly or probably caused by drug-drug interactions as per DIPS<sup>(17)</sup>.  
32 Given this deprescribing, especially in those on a polypharmacy, could play an important role in  
33 reducing ADR burden.

### 34 35 **Comparison with Pirmohamed 2004**

36  
37 Pirmohamed et al 2004 <sup>(8)</sup> was a large prospective study of admission ADRs in two Liverpool  
38 hospitals, the large university teaching hospital used in this study and a smaller district general  
39 hospital. This found an ADR prevalence in hospital admissions of 6.5%, suggesting there has been a  
40 significant increase since 2004. Numerous clinical reasons could have influenced this including  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 changes in population demographics, increased morbidity and prescribing patterns. Some of the  
4 increase may be because pharmacovigilance has improved over the last 20 years, and the adverse  
5 reaction profile of drugs is more comprehensive. For example, following a large case control study by  
6 Ernst et al <sup>(24)</sup>, an increased risk of pneumonia and dose dependant 30-day mortality from steroid  
7 based inhalers in COPD patients was added as a side effect to the British National Formulary. Over  
8 10% of the ADRs in this study are attributable to this. Some ADRs were also secondary to newer  
9 therapies including chemotherapies and monoclonal antibodies that have been developed since  
10 2004.

11  
12 In 2004 two of the main causative medicines were NSAIDs (11.8%) and the antiplatelets (aspirin and  
13 clopidogrel) (23.8%). In this study these medicines were implicated in 0.85% and 7.4% of the ADRs  
14 respectively. Despite the increase in total ADRs from 2004 this would suggest a large proportional  
15 reduction. This is likely due to changes in prescribing practice including co-administration of proton  
16 pump inhibitors (PPI). However, this has promoted PPIs as a cause of ADRs from very few cases to  
17 being responsible for 12.1% of ADRs in this study. The majority of the reactions were only mild  
18 transient electrolyte disturbances, with only a single severe associated ADR of Clostridium difficile.

19  
20 In recent years, concerns of an opiate crisis due to excessive community prescription has occurred in  
21 the USA <sup>(25)</sup>. In this study, opiate medications accounted for 5.1% of ADRs which is similar to the 6.0%  
22 found in 2004. This suggests that proportionally there has not been a significant increase in  
23 prescription opiate related admissions locally. Of the related 13 events, the majority were non-  
24 lethal, with only 2 cases exhibiting respiratory depression but with no permanent harm following  
25 reversal.

26  
27 Changes in prescribing patterns and subsequent ADRs may reflect increasing multimorbidity and  
28 polypharmacy. However, as such data was not previously collected this cannot be directly compared.  
29 Furthermore, methodological differences may have contributed as this study did not include any  
30 data from a district general hospital or surgical admissions. Additionally, screening and data  
31 collection was completed by medical doctors and clinical pharmacologists, whereas previously it was  
32 completed by a number of healthcare professionals. Thus, differences in clinical and diagnostic  
33 experience could also be responsible for some increased identification of ADRs.

### 34 **Multimorbidity and Polypharmacy**

35  
36 Multimorbidity and polypharmacy were both associated with admission ADR on univariate analysis.  
37 Those with an ADR were taking on average 35% more medicines than those without (10.5 v 7.8),  
38 which is an established risk factor for ADRs<sup>(26)</sup>. Despite this polypharmacy must not be conflated with  
39

1  
2  
3 inappropriate prescribing as some patients, particularly those that are multimorbid, require multiple  
4 medicines to optimise their LTCs with associated positive outcomes. This study did not assess the  
5 appropriateness of all community prescriptions, but only of those that directly caused an ADR via the  
6 avoidability assessment tool.  
7  
8  
9

10 The mean number of comorbidities for the entire admitted population was 5.4. Although we do not  
11 have direct data from 2004 for comparison it is reported that the incidence of multimorbidity has  
12 been increasing <sup>(2)</sup>. The ADR group on average had 17% more co-morbidities than the non ADR group  
13 (6.1 vs 5.2), which is a known risk factor <sup>(26)</sup>. Although total number of co-morbidities is relevant, it  
14 does not to give insight into disease severity which may subsequently influence the number of  
15 medications a patient is taking. For example, hypertension or type 2 diabetes managed with lifestyle  
16 factors would produce less medication burden than more advanced disease. Furthermore, some  
17 conditions and their management are known to predispose to prescribing cascades and therefore  
18 polypharmacy <sup>(26,27)</sup>. This may explain why the number of comorbidities was not significant following  
19 logistic regression analysis, with only age, number of medications and liver impairment being  
20 significant factors.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Cost analysis**

31  
32 ADRs are a significant cost burden on the NHS, and in this study accounted for £1 in every £8 spent  
33 on the care of non-elected hospital admissions. Put into perspective, the total cost of admissions  
34 related to ADRs over the 1-month study period (£490,716) is comparable with the annual cost of  
35 chemotherapy procurement by the hospital in which the study was conducted. When extrapolated  
36 nationally, our estimate of £2.21 bn for admissions resulting from ADRs exceeds the costs of all  
37 outpatient procedures for NHS England. Previous cost analyses of medication-related harm in  
38 England provide annual estimates of £1.9 bn based on an extrapolation from Pirmohamed et al  
39 (2004)<sup>(28)</sup>, £529m for potentially avoidable adverse drug reaction-related admissions <sup>(29)</sup>, and £396m  
40 for discharged elderly people <sup>(30)</sup>.  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Strengths and weaknesses**

50  
51 Key strengths include that data was collected prospectively and notes were reviewed by specialists  
52 in clinical pharmacology and general internal medicine. This optimised the reliability of collected  
53 data and identification of ADRs. The availability of patient-level cost data, reflecting the actual spend  
54 on hospital care, represents another strength over many previous cost analyses.  
55  
56  
57

58 Using standardised criteria to identify and classify ADRs improves objectivity and reproducibility as  
59 evidenced by levels of concordance >90% between reviewers. However, some elements of the  
60

1  
2  
3 criteria can be subjective and rely on reviewer clinical experience. Furthermore, many of the medical  
4 conditions and side effects attributed to an ADR may have occurred regardless of prescription, for  
5 example regarding steroid inhalers and the increased risk of pneumonia in COPD patients. A  
6  
7 limitation of our study is that we have not concurrently assessed the benefits of taking medicines in  
8  
9 individual patients.  
10

11  
12 Liverpool is ranked as the most deprived major city in England, an established factor in predicting  
13 increased morbidity<sup>(31)</sup>. With the disparity between the most and least deprived areas in England  
14 having increased since the 1990's<sup>(32)</sup>, changes in local population may have influenced differences  
15 found from 2004 as well as limit the utility of extrapolation of data nationally.  
16  
17  
18

## 19 20 **CONCLUSION**

21  
22 This study found ADRs contributed or directly caused 16.6% of all admissions with an associated  
23 mortality rate of 0.34%. Factors associated with an ADR on logistic regression included age, number  
24 of medications and liver impairment. The data suggests ADRs place a significant and increasing  
25 burden on patients and healthcare services with associated financial implications. Using patient-level  
26 cost data the projected annual cost of ADR admissions to the NHS in England is £2.21 bn. With 39.4%  
27 of these ADRs identified as avoidable or potentially avoidable future efforts should be directed to  
28 reduce this burden. Reducing inappropriate polypharmacy should be a major aim for preventing  
29 ADRs.  
30  
31  
32  
33  
34  
35

## 36 37 **DECLARATIONS**

38  
39 The authors have read the BMJ policy on declaration of interests. MP receives research funding from  
40 various organisations including the MRC and NIHR. He has also received partnership funding for the  
41 following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly  
42 and Novartis); a PhD studentship jointly funded by EPSRC and Astra Zeneca; and grant funding from  
43 Vistagen Therapeutics. He has also unrestricted educational grant support for the UK  
44 Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has  
45 developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this.  
46 He is part of the IMI Consortium ARDAT ([www.ardat.org](http://www.ardat.org)). None of these of funding sources have  
47 been used for the current paper.  
48  
49  
50  
51  
52  
53

54  
55 There were no patient contributors or co-authors in this study.  
56

57  
58 Approval was granted by Liverpool University Hospital Foundation NHS Trust clinical audit and  
59 service evaluation department.  
60

1  
2  
3 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
4 all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis  
5 to the BMJ Publishing Group Ltd ("BMJ"), and its Licencees to permit this article (if accepted) to be  
6 published in The BMJ's editions and any other BMJ products and to exploit all subsidiary rights, as  
7 set out in our licence.  
8  
9  
10  
11

### 12 **Key messages bullet points**

- 15 • Adverse drug reactions directly caused or contributed to 16.6% of all medical admissions
- 16 • Age, number of medications, multimorbidity, liver impairment and renal impairment are  
17 important factors associated with ADRs
- 18 • The cost of ADRs when extrapolated nationally may be as high as £2.21 bn per annum in  
19 England.  
20  
21  
22  
23

### 24 **Summary boxes**

#### 25 ***What we already know on this topic***

- 26 • In 2004 a large prospective study in the UK found adverse drug reactions accounted for  
27 6.5% of hospital admissions
- 28 • Polypharmacy and multimorbidity are becoming increasingly prevalent in the UK  
29 population.  
30  
31  
32  
33  
34  
35  
36

#### 37 ***What this study adds***

- 38 • 16.6% of admissions directly or contributed by an ADR, a significant increase from 2004.
- 39 • The mortality attributable to adverse drug reactions was 0.34%.
- 40 • The projected annual financial cost to NHS in England is £2.1 bn
- 41 • Key associated factors included age, number of medications, multimorbidity, renal and  
42 hepatic impairment.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]
2. Addressing the global challenge of multimorbidity, The Academy of Medical Sciences [Internet]. *Acmedsci.ac.uk*. 2020 [cited 15 December 2020]. Available from: <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity/evidence-submission>.
3. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol* 2012;22(17):R741-52. doi: 10.1016/j.cub.2012.07.024 [published Online First: 2012/09/15]
4. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017;17(1):230. doi: 10.1186/s12877-017-0621-2 [published Online First: 2017/10/12]
5. NHS Business Service Authority, Wessex Academic Health Science Network. (2017) Medicines Optimisation: Polypharmacy <https://www.nhsbsa.nhs.uk/epact2/epact2-dashboard/specifications/medicinesoptimisation-polypharmacy>.
6. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. *BMC Med* 2015;13:74. doi: 10.1186/s12916-015-0322-7 [published Online First: 2015/04/19]
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998;279(15):1200-5. doi: 10.1001/jama.279.15.1200 [published Online First: 1998/04/29]
8. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 2004;329(7456):15-9. doi: 10.1136/bmj.329.7456.15 [published Online First: 2004/07/03]
9. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. *Drug Saf* 2015;38(5):437-53. doi: 10.1007/s40264-015-0281-0 [published Online First: 2015/03/31]
10. Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bull Emerg Trauma* 2019;7(4):339-46. doi: 10.29252/beat-070401 [published Online First: 2019/12/21]
11. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in Scotland. *Pharm World Sci* 2008;30(6):854-62. doi: 10.1007/s11096-008-9240-5 [published Online First: 2008/07/26]
12. Bednall R, McRobbie D, Hicks A. Identification of medication-related attendances at an A & E department. *J Clin Pharm Ther* 2003;28(1):41-5. doi: 10.1046/j.0269-4727.2003.00461.x [published Online First: 2003/02/28]



- 1  
2  
3 13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet*  
4 2000;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9 [published Online First: 2000/11/10]  
5  
6  
7 14. Davies DM, Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM,  
8 ed. Textbook of adverse drug reactions. Oxford: Oxford University Press,1991:18–45  
9  
10 15. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the  
11 Liverpool adverse drug reaction causality assessment tool. *PLoS One* 2011;6(12):e28096. doi:  
12 10.1371/journal.pone.0028096 [published Online First: 2011/12/24]  
13  
14 16. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse  
15 drug reactions. *Am J Hosp Pharm* 1992;49(9):2229-32. [published Online First: 1992/09/01]  
16  
17 17. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. *Ann*  
18 *Pharmacother* 2007;41(4):674-80. doi: 10.1345/aph.1H423 [published Online First: 2007/03/29]  
19  
20 18. Bracken LE, Nunn AJ, Kirkham JJ, et al. Development of the Liverpool Adverse Drug Reaction  
21 Avoidability Assessment Tool. *PLoS One* 2017;12(1):e0169393. doi: 10.1371/journal.pone.0169393  
22 [published Online First: 2017/01/04]  
23  
24 19. Joint Formulary Committee (2019) BNF 78: September 2019-March 2020. London:  
25 Pharmaceutical Press.  
26  
27 20. England, N., 2021. NHS England » National Cost Collection for the NHS. [online] England.nhs.uk.  
28 Available at: <<https://www.england.nhs.uk/national-cost-collection/#ncc1819>> [Accessed 4 January  
29 2021].  
30  
31 21. Patel PB, Patel TK. Mortality among patients due to adverse drug reactions that occur following  
32 hospitalisation: a meta-analysis. *Eur J Clin Pharmacol* 2019;75(9):1293-307. doi: 10.1007/s00228-  
33 019-02702-4 [published Online First: 2019/06/12]  
34  
35 22. Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse  
36 drug reactions and preventability of adverse drug reactions--a meta-analysis. *PLoS One*  
37 2012;7(3):e33236. doi: 10.1371/journal.pone.0033236 [published Online First: 2012/03/23]  
38  
39 23. Coleman JJ, Pontefract SK. Adverse drug reactions. *Clin Med (Lond)* 2016;16(5):481-85. doi:  
40 10.7861/clinmedicine.16-5-481 [published Online First: 2016/10/05]  
41  
42 24. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious  
43 pneumonia. *Thorax* 2013;68(11):1029-36. doi: 10.1136/thoraxjnl-2012-202872 [published Online  
44 First: 2013/10/17]  
45  
46 25. Chisholm-Burns MA, Spivey CA, Sherwin E, et al. The opioid crisis: Origins, trends, policies, and  
47 the roles of pharmacists. *Am J Health Syst Pharm* 2019;76(7):424-35. doi: 10.1093/ajhp/zxy089  
48 [published Online First: 2019/07/31]  
49  
50 26. Brath H, Mehta N, Savage RD, et al. What Is Known About Preventing, Detecting, and Reversing  
51 Prescribing Cascades: A Scoping Review. *J Am Geriatr Soc* 2018;66(11):2079-85. doi:  
52 10.1111/jgs.15543 [published Online First: 2018/10/20]  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 27. Piggott KL, Mehta N, Wong CL, et al. Using a clinical process map to identify prescribing cascades  
4 in your patient. *BMJ* 2020;368:m261. doi: 10.1136/bmj.m261 [published Online First: 2020/02/23]  
5  
6  
7 28. Compass. Adverse drug reactions wastes NHS £2BN reveals Compass. Compass; London; 2008.  
8 [Cited in <https://www.theguardian.com/society/2008/apr/03/nhs.drugsandalcohol>]  
9  
10 29. National Institute for Health and Care Excellence. Costing statement: Medicines optimisation.  
11 Implementing the NICE guideline on medicines optimisation (NG5). March 2015.  
12 <https://www.nice.org.uk/guidance/ng5/resources/costing-statement-6916717>  
13  
14 30. Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults  
15 following hospital discharge: a multicentre prospective study in the UK. *Br J Clin Pharmacol*  
16 2018;84(8):1789-97. doi: 10.1111/bcp.13613 [published Online First: 2018/05/24]  
17  
18 31. English indices of deprivation 2019 [Internet]. GOV.UK; 2020 [cited 31 August 2020]. Available  
19 from: <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019>.  
20  
21  
22 32. Newton JN, Briggs AD, Murray CJ, et al. Changes in health in England, with analysis by English  
23 regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease  
24 Study 2013. *Lancet* 2015;386(10010):2257-74. doi: 10.1016/S0140-6736(15)00195-6 [published  
25 Online First: 2015/09/19]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables

**Table 1 – Drugs implicated in patient episodes with adverse drug reactions\***

Drug class	No of ADRs (%)	Offending drug	ADR
Diuretics	31 (14.2%)	Furosemide (13), spironolactone (8), bumetanide (6), bendroflumethiazide (2), coamilofruse (1), indapamide (1)	Renal impairment (18), electrolyte derangement (12), postural hypotension (1)
Steroid inhaler	27 (12.4%)	Steroid inhaler (27)	Pneumonia (26), Oral Thrush (1)
Anticoagulants	21 (9.6%)	Warfarin (7), apixaban (5), edoxaban (4), rivaroxaban (4), enoxaparin (1)	Minor bleeding (10), anaemia (4), intracranial haemorrhage (4), Gastrointestinal bleed (3)
Proton pump inhibitor	18 (8.3%)	Lansoprazole (9), omeprazole (6), pantoprazole (3)	Hypomagnesaemia (11), hyponatraemia (6), C.Diff (1)
Antiplatelet	16 (7.4%)	Aspirin (13), clopidogrel (3)	Intracranial haemorrhage (5), Gastrointestinal bleed (4), minor bleeding (4), anaemia
Chemotherapy	16 (7.3%)	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Deranged electrolytes (1), Rash (1), Thrombocytopenia (1)
ACE-inhibitor / angiotensin receptor blocker	14 (6.4%)	Losartan (4), ramipril (4), irbesartan (3), candesartan (1), lisinopril (1), perindopril (1)	Renal impairment (9), postural hypotension (3), hyperkalaemia (1), renal failure (1)
Antidepressants & Antipsychotics	13 (6.0%)	Mirtazapine (2), sertraline (2), sulpride (2), carbamazepine (1), dosulepin (1), nortriptyline (1), olanzapine (1), risperidone (1)	Confusion (3), hyponatraemia (3), parkinsonism (3), constipation (1), gastrointestinal bleed (1), prolonged QTc (1)
Opiates	13 (6.0%)	Codeine (5), morphine sulphate (3), oxycodone (2), tramadol (2), buprenorphine (1)	Constipation (6), confusion (4), respiratory depression (2), hallucinations (1)
Other	49 (22.4%)	Other (49)	Other (49)
*In those with multiple ADRs only the most severe ADR was included in this table, as defined by the adapted Hartwig severity scale <sup>(16)</sup> . See supplementary material for full list.			

**Table 2– Deaths directly related to the adverse reaction (Adapted Hartwig class 7b)**

Medication	Number	Cause of death
Chemotherapy	2	Neutropenic sepsis (2)
Aspirin	1	Intracranial haemorrhage
Edoxaban	1	Gastrointestinal bleed

For peer review only

**Table 3 – Characteristics of patients with and without adverse drug reactions**

	<b>ADR group</b>	<b>Non ADR group</b>	<b>Total</b>
<b>Number of admissions</b>	218	969	1187
<b>Age</b>			
Mean (s.d.)	73.2 (14.5)	66.7 (19.2)	67.9 (18.6)
<b>Male (%)</b>	106 (48.6%)	455 (47.0%)	561 (47.3%)
<b>Number of medicines</b>			
Mean (s.d.)	10.5 (4.6)	7.8 (5.1)	8.3 (5.1)
<b>Polypharmacy (%)</b>	199 (91.3%)	706 (72.9%)	905 (76.2%)
<b>Number of co-morbidities</b>			
Mean (s.d.)	6.1 (3.0)	5.2 (3.3)	5.4 (3.2)
<b>Multimorbid (%)</b>	216 (99.1%)	875 (90.3%)	1091 (91.9%)
<b>Liver impairment * (%)</b>	15 (6.9%)	27 (2.8%)	42 (3.5%)
<b>Renal impairment ** (%)</b>	24 (11.0%)	66 (6.8%)	90 (7.6%)
* Liver impairment defined as Chronic Liver Disease			
** Renal impairment defined as Chronic Kidney Disease stage IV or V			

**Table 4: Logistic regression analysis of patients with and without adverse drug reactions**

	<b>Univariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>	<b>Multivariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>
<b>Age</b>	1.02 (1.01, 1.03)	<0.001	1.02 (1.01, 1.03)	<0.001
<b>Sex (Male)</b>	1.07 (0.80, 1.44)	0.659		
<b>Number of medicines</b>	1.11 (1.07, 1.14)	<0.001	1.10 (1.07, 1.13)	<0.001
<b>Number of comorbidities</b>	1.08 (1.04, 1.13)	<0.001		
<b>Liver impairment (CLD)</b>	2.58 (1.35, 4.93)	0.004	3.23 (1.63, 6.40)	<0.001
<b>Renal impairment (CKD stage 4 or 5)</b>	1.69 (1.04, 2.78)	0.036		

## Supplementary material - Full list of Adverse reactions by drug class

Drug Class	Number of associated ADRs	Medications implicated	Adverse reaction
Diuretics	31	Furosemide (13), Spironolactone (8), Bumetanide (6), Bendroflumethiazide (2), Coamilofruse (1), Indapamide (1)	Renal impairment (18), Electrolyte derrangement (12), Postural hypotension (1)
Steroid inhaler	27	Steroid inhaler (27)	CAP (26), Oral Thrush (1)
Anticoagulants	21	Warfarin (7), Apixaban (5), Edoxaban (4), Rivaroxaban (4), Enoxaparin (1)	Minor bleeding (10), Anaemia (4), Intracranial haemmhorage (4), GI bleed (3)
PPI	18	Lansoprazole (9), Omeprazole (6), Pantoprazole (3)	Hypomagnasaemia (11), Hyponatraemia (6), C.Diff (1)
Antiplatelets	16	Aspirin (13), Clopidogrel (3)	Intracranial haemoorrhage (5), GI bleed (4), Minor bleeding (4), Anaemia
Chemotherapy	16	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Derranged electrolytes (1), Rash (1), Thromocytopenia (1)
ACE-i/ARB	14	Losartan (4), Ramipril (4), Irbesartan (3), Candesartan (1), Lisinopril (1), Perindopril (1)	Renal impairment (9), Postural hypotension (3), Hyperkalaemia (1), Renal failure (1)
Antidepressants & antipsychotics	13	Mirtazapine (2), Sertraline (2), Sulpride (2), Carbamazepine (1), Dosulepin (1), Nortriptyline (1), Olanzapine (1), Risperidone (1)	Confusion (3), Hyponatraemia (3), Parkinsonism (3), Constipation (1), GI bleed (1), Prolonged QTc (1)
Opiates	13	Codeine (5), Morhpine Sulphate (3), Oxycodone (2), Tramadol (2), Buprenorphine (1)	Constipation (6), Confusion (4), Respiratory Depression (2), Hallucinations (1)
B-blockers	9	Bisoprolol (6), Atenolol (1), Nebivolol (1), Propanolol (1)	Bradycardia (5), Postural hypotension (4)
Insulin	7	Insulin (7)	Hypoglycaemia (4), Hypoglycaemic seizures (2)
CCB	6	Amlodipine (4), Ivabradine (1), Diltiazem (1)	Postural hypotension (5), Prolonged QTc (1)
Bladder anticholinergics	6	Solifenacin (4), Tolterodine (1), Tropsium (1)	Confusion (4), Constipation (2)
Immunosuppressants	5	MMF (3), Tacrolimus (2)	Sepsis (5)
Antimicrobials	4	Penicillin (2), Aciclovir (1), Azithromycin (1)	Angioedema (1), Rash (1), Renal impairment (1), Prolonged QTc (1)
Oral anti-diabetics	4	Gliclazide (2), Empagliflozin (1), Pioglitazone (1)	Hypoglycaemia (2), Heart Failure (1), Urinary Tract infection (1)

Monoclonals	3	Afatanib (1), Pembrolizumab (1), Ruxolitinib (1)	Liver toxicity (1), Pneumonitis (1), Sepsis (1)
Statins	2	Atorvastatin (1), Simvastatin (1)	Myopathy (2)
Levodopa	2	Co-beneldopa (1), Co-careldopa (1)	Postural Hypotension (2)
PTH Analogues	2	Alfacalcidol (1), Calcitriol (1)	Hypercalcaemia (2)
NSAIDs	2	Naproxen (2)	ACS (1), GI Bleed (1)
Benzodiazepines	2	Lorazepam (1), Tempezepam (1)	Confusion (2)
Baclofen	1	Baclofen (1)	Constipation (1)
Amitriptyline	1	Amitriptyline (1)	Confusion (1)
Leviteracetam	1	Leviteracetam (1)	Renal impairment (1)
Doxazocin	1	Doxazocin (1)	Postural hypotension (1)
Nefopam	1	Nefopam (1)	Delirium (1)
Quinine	1	Quinine (1)	Prolonged QTc (1)
Lithium	1	Lithium (1)	Lithium Toxicity (1)
Laxatives	1	Laxatives (1)	Diarrhoea (1)
Bisphosphonates	1	Alendronic Acid (1)	Erosive Gastritis (1)
Thyroxine	1	Levothyroxine (1)	Tachyarrhythmia (1)
Zopiclone	1	Zopiclone (1)	Confusion (1)
Phosphodiesterase inhibitor	1	Uniphyllin (1)	Nausea (1)



## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	4
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	4
		(e) Describe any sensitivity analyses	n/a

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	4
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	16
		(b) Indicate number of participants with missing data for each variable of interest	4
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16
		(b) Report category boundaries when continuous variables were categorized	16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Table 4
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Additional

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055551.R1
Article Type:	Original research
Date Submitted by the Author:	27-Jan-2022
Complete List of Authors:	Osanlou, Rostam; University of Liverpool, Department of Pharmacology and Therapeutics; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Pharmacology and Therapeutics Walker, Lauren; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics Hughes, Dyfrig; Bangor University, Centre for Health Economics and Medicines Evaluation Burnside, Girvan; University of Liverpool, Department of Biostatistics Pirmohamed, Munir; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Health economics
Keywords:	Adverse events < THERAPEUTICS, CLINICAL PHARMACOLOGY, HEALTH ECONOMICS, INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Rostam Osanlou<sup>1,2</sup>, Lauren Walker<sup>1,2</sup>, Dyfrig Hughes<sup>3</sup>, Girvan Burnside<sup>4</sup>, Munir Pirmohamed<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE

<sup>2</sup>Liverpool University Hospital Foundation NHS Trust, Prescot Street, Liverpool, L7 8XP

<sup>3</sup>Centre for health economics and medicines evaluation, University of Bangor, College Road, Bangor LL57 2DG

<sup>4</sup>Department of Biostatistics, University of Liverpool, Liverpool L69 3GE

Author for correspondence:

Prof M Pirmohamed  
Institute of Systems, Molecular and Integrative Biology (ISMIB)  
University of Liverpool  
Block A: Waterhouse Building  
1-5 Brownlow Street  
Liverpool L69 3GL  
[munirp@liverpool.ac.uk](mailto:munirp@liverpool.ac.uk)

**Word count:** 3106

**Keywords:** Adverse drug reaction, ADR, Multimorbidity, Polypharmacy

## ABSTRACT

**Objective** To ascertain the burden and associated cost of adverse drug reactions (ADRs), polypharmacy and multimorbidity through a prospective analysis of all medical admissions to a large University teaching hospital over a one-month period.

**Design** Prospective observational study.

**Setting** Liverpool University Hospital Foundation NHS Trust, England.

**Participants** All medical admissions with greater than 24-hour stay over a one-month period.

**Main outcome measures** Prevalence of admissions due to an ADR and associated mortality. Prevalence and association of multimorbidity and polypharmacy with ADRs. Estimated local financial cost of admissions where ADR was a contributing or main reason for admission with projected costs for NHS in England.

**Results** There were 218 identified patient admissions with an ADR giving a prevalence of 18.4%. The majority of these (90.4%) were ADRs that directly resulted in or contributed to admission. ADRs thus accounted for 16.5% of total admissions. Those with an ADR were on average taking more medicines (10.5 vs 7.8  $p<0.01$ ) and had more co-morbidities than those without an ADR (6.1 vs 5.2,  $p<0.01$ ). Drugs most commonly implicated were diuretics, steroid inhalers, anticoagulants & antiplatelets, proton pump inhibitors, chemotherapeutic agents and antihypertensives. 40.4% of ADRs were classified avoidable or possibly avoidable. The mortality rate due to an ADR was 0.34%. The average length of stay for those with an ADR was 6 days. Direct one month cost to the Trust from ADR admissions was £490,716. Extrapolated nationally the projected annual cost to the NHS in England is 2.21 billion.

**Conclusion** The local prevalence of admission and mortality from ADRs are higher than previously reported. Important factors that could be contributing to this include polypharmacy and multimorbidity. ADRs place a significant burden on patients and healthcare services with associated financial implications. Reducing inappropriate polypharmacy should be a major aim for preventing ADRs.

**Strengths and limitations of this study:**

- Over 1000 medical admissions were individually reviewed by specialists in clinical pharmacology and general internal medicine in this prospective analysis of adverse drug reactions.
- Standardised criteria, as listed in methods, were used to identify and classify ADRs. This improves the objectivity and reproducibility of the analysis.
- Extrapolating the cost analysis nationally based on medical admissions locally may be unreliable due to differences including local population and services.
- This study does not take into account how commonly each medicine that caused an ADR is prescribed in the local community.

## INTRODUCTION

Improved living conditions, and better access to and quality of medical care, has led to increased life expectancy and the associated accumulation of Long Term Conditions (LTC) <sup>(1)</sup>. According to a report by the Academy of Medical Sciences, multimorbidity is a growing issue globally, particularly in more economically developed countries where it is now considered the norm not the exception <sup>(2)</sup>. Age is the single biggest risk factor for LTCs such as cancer, cardiovascular disease and neurodegeneration in developed countries. An ageing population is therefore at increased risk of polypharmacy <sup>(3)</sup>. Care for people with multiple LTCs is often stretched across various single-organ specialists leading to siloed specialty prescribing and increasingly complex medication regimens.

Polypharmacy is the concurrent use of multiple medications by an individual. Numerical definitions vary but it is most commonly defined as taking 5 or more regular medications <sup>(4)</sup>. The Wessex Academic Health Science Network have developed a set of prescribing comparators to better understand both the numerical and risk-related factors involved in the variation of prescribing of multiple medicines <sup>(5)</sup>. Appropriate polypharmacy can improve health outcomes in multimorbidity, the co-occurrence of two or more long term conditions. In contrast, potentially inappropriate polypharmacy, wherein the risk of harms from individual medicines may outweigh their benefit in the context of the prescription as a whole, is associated with poor adherence and an increased risk of adverse-drug reactions (ADRs) and interactions <sup>(6)</sup>. ADRs are an important cause of morbidity and mortality, with significant health implications and associated economic burden. Landmark studies in the USA in 1998 <sup>(7)</sup> and the UK in 2004 <sup>(8)</sup> found ADRs to be related to 6.7% and 6.5% of hospital admissions, respectively. More recent systematic reviews have reported figures ranging from 3.6% <sup>(9)</sup> to 15.6% <sup>(10)</sup>. Potential reasons for variation in findings include the heterogeneity of methodologies and populations studied.

Addressing avoidable ADRs due to inappropriate prescribing is important to reduce the burden on patients and healthcare systems. There are few adult observational studies of admission ADRs in the United Kingdom that are not focused on a specific populations or drug reactions. To our knowledge there are only 3 in the last 20 years <sup>(8,11,12)</sup>. In 2016, it was estimated that £1.3-3 billion could be saved in the NHS budget through reducing inappropriate and inefficient medicines usage<sup>(13)</sup>.

The aim of this study was to determine the current impact of ADRs on medical admissions, their association with multimorbidity and polypharmacy, and quantify the economic impact on the National Health Service (NHS). The population studied is broadly geographically comparable to that of Pirmohamed et al 2004 <sup>(8)</sup>.



## METHODS

Study data was collected for one month in the city centre site of the Liverpool University Hospital Foundation NHS Trust, a large teaching hospital in Merseyside, England. Approval for data collection was obtained through governance processes within the Trust. All patients referred via the medical assessment unit that were admitted for >24 hours were included. These were mostly via the emergency department but also included primary care referrals and admissions from outpatient clinics. Patients admitted via medicine but transferred to other centres for emergency treatment (such as primary coronary intervention) within 24 hours were included, as their expected inpatient stay would be >24 hours. Information including e-notes, community drug prescriptions and investigations were reviewed to determine if an ADR occurred. An ADR was defined using the Edwards and Aronson criteria<sup>(14)</sup>. This does not include any type of drug overdose or relapse due to noncompliance. Cases were then defined as either the primary cause of admission, contributing factor or a co-incidental finding and assessed against the following criteria:

- Classification of the reaction as per Rawlins and Thompson<sup>(15)</sup>
- Causality as per the Liverpool causality assessment tool (LCAT)<sup>(16)</sup>
- Severity as per the adapted Hartwig severity scale (AHSS)<sup>(17)</sup>
- Interactions as per the drug interaction probability scale (DIPS)<sup>(18)</sup>
- Avoidability as per the Liverpool ADR avoidability assessment tool (LAAT)<sup>(19)</sup>

Factors that suggested an ADR include if it was consistent with the known adverse effect profile of the drug as per the British National Formulary<sup>(20)</sup>, if there was a temporal relationship, and if alternate causes were excluded with history and investigation. Community drug prescription were verified and reviewed with patient electronic notes. This data was available for all admitted patients. If it was documented in the notes that a patient was not taking a medicine listed on their prescription this was not included in our analysis.

Identification of ADRs and subsequent assessment of the above criteria was completed by authors RO and LW. Where consensus was not reached it was assessed by third reviewer MP. Of the 258 patient episodes with possible identified ADRs, there was initial agreement on 236 (91%). For the remainder consensus was obtained following joint review with MP.

Patient Level Information and Costing System (PLICS) data reporting healthcare resource group and hospital costs were obtained from the Liverpool University Hospitals NHS Foundation Trust finance office. Total costs were summed for episodes of admitted care resulting from ADRs (a), and for all other admissions (where ADR was a contributory factor, coincidental, or unrelated; (b)). In order to

1  
2  
3 extrapolate costs, totals for non-elective short and long stay, and regular day or night admissions, for  
4 NHS England (c), were obtained for 2018-19 <sup>(21)</sup>. Nationally projected costs were estimated as  
5 (a.c)/(a+b).  
6  
7

### 8 9 **Ethics Approval**

10  
11 Approval for this study was granted by Liverpool University Hospital Foundation NHS Trust clinical  
12 audit and service evaluation department (Project number 7580).  
13  
14

### 15 16 **Patient and public involvement**

17  
18 The research question was developed due to the impact ADRs have on patients by causing  
19 admissions to hospital. There were no patient contributors or co-authors in this study.  
20  
21

### 22 23 **STATISTICAL ANALYSIS**

24  
25 Statistical analysis was performed using the SAS software (Version 9.4, SAS Institute, Cary, NC, USA).  
26 The results are presented either as means and standard deviations or frequencies and percentages.  
27 Associations between patient characteristics and admission type (ADR/Non-ADR) were investigated  
28 using univariable and multivariable logistic regression, with associations presented as odds ratios  
29 (OR) with 95% confidence intervals. The multivariable model used backwards selection with a  
30 probability of exclusion of 0.1. A P value < 0.05 was regarded as statistically significant.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

There were 1,187 admissions with 218 patients with an ADR (18.4%). As some of those had multiple ADRs 235 were identified in total.

### Characteristics of adverse drug reactions

145 (66.5%) of the ADRs were the primary cause of admission, with 51 (23.4%) contributing to admission, and 22 (10.1%) co-incidental findings that alone would not have required hospital stay. Thus, ADRs directly caused or contributed to 16.6% of all admissions. Using the Liverpool causality assessment tool<sup>(16)</sup> 45 (20.6%) were graded as definite, 79 (36.2%) as probable, and 94 (43.1%) as possible ADRs. 40 (18.4%) were graded as avoidable and 46 (21.1%) as possibly avoidable using LAAT criteria<sup>(19)</sup>. 64 (29.4%) of ADRs were possibly or probably caused by a drug-drug interaction as per DIPS<sup>(18)</sup>. 188 (86.2%) were Type A reactions as defined by Rawlins and Thompson<sup>(15)</sup> and 30 (13.8%) Type B. 164 (75.2%) of the ADRs were documented as recognised or acted on by the admitting medical team. The main drugs implicated in ADRs are listed in table 1. There were 4 ADRs (1.8%) that directly resulted in death and a further 5 that were implicated or a contributing factor to death (2.3%) (table 2). The mortality rate directly from ADRs, from all admissions, was therefore 0.42%. Median length of stay of patients with an ADR was 6 days.

### Comparison of patients with and without adverse drug reactions

Table 3 shows descriptive statistics of patients with and without ADRs. In the patients with ADRs, as would be expected, liver and renal impairment were more prevalent compared to patients without ADRs (6.8% vs 2.8%,  $p < 0.004$ ).

Logistic regression results are presented in Table 4. Patients with ADRs were older than those without (mean age 73.2 (14.5) vs 66.7 (19.2), OR 1.02 (1.01, 1.03)) and were taking more medicines (mean 10.5 (4.6) vs 7.8 (5.1), OR 1.11 (1.07, 1.14)), with polypharmacy present in 91%, compared to 73% in the non-ADR group. They had more comorbidities (mean 6.1 (3.0) vs 5.2 (3.3), OR 1.08 (1.04, 1.13)), although this variable was not included in the multivariable model (possibly due to its correlation with number of medicines). Those with ADRs were more likely to have liver impairment (6.9% vs 2.8%, OR 2.58 (1.35, 4.93)) and renal impairment (11.0% vs 6.8%, OR 1.69 (1.04, 2.78)).

Healthcare Resource Group (HRG) costs were available for 214 (98.2%) patients in the ADR group, and 950 (98.0%) patients in the non-ADR group. Mean costs per episode of care were £2,293 (95% CI 1918, 2668) and £2,131 (95% CI 1899, 2364), respectively. The total costs of admissions resulting from ADR were £309,207, representing 12.3% of the costs of the whole cohort over the 1-month sampling frame. Admissions where ADR was a contributory factor cost £138,762 (5.5%); and where

1  
2  
3 ADR was coincidental, the cost was £42,747 (1.7%). The total costs of non-elective short and long  
4 stays, and regular day or night admissions across all NHS trusts and NHS foundation trusts in England  
5 was £17.98 billion in 2018-19, of which we estimate £2.21 billion were due to admissions resulting  
6 from ADRs.  
7  
8  
9

## 10 **DISCUSSION**

11  
12  
13 This study found ADRs in 18.4% of hospital admissions. In 16.6% of admissions, it was the primary  
14 cause or a contributing cause suggesting ADRs have a significant burden on hospital admissions. This  
15 is over twice as high as the 6.5% found in Pirmohamed 2004<sup>(8)</sup> which consisted of broadly the same  
16 geographical area. Most commonly implicated medicines included diuretics, steroid based inhalers,  
17 anticoagulants, proton pump inhibitors, antiplatelets, chemotherapy agents, anti-hypertensives,  
18 opiates and antidepressants/antipsychotics (Table 1). It is important to consider this study does not  
19 reflect how often each of these medicines are prescribed in the community. Some of the medicines  
20 implicated with the highest number of ADRs and deaths may be a reflection of how commonly they  
21 are prescribed. Furthermore, the use of these medicines also provides clinical benefits that reduce  
22 morbidity, mortality and need for hospital admissions, and this is not taken into account by our data.  
23 Direct mortality from ADRs was 0.42% which is also an increase from Pirmohamed 2004 (0.15%)<sup>(8)</sup>  
24 and twice as high as a recent meta-analysis<sup>(22)</sup>.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Approximately, 40% of ADRs were classified as avoidable or possibly avoidable. This is consistent  
35 with previous studies which found significant proportions of ADRs that lead to hospital admissions  
36 are potentially avoidable<sup>(23)</sup>. Given this, future efforts should be targeted at reducing these  
37 preventable admissions. Key strategies that can mitigate for ADRs include stratifying patients by  
38 susceptibility prior to medication initiation using key information such as co-morbidities,  
39 concomitant medications and renal and hepatic function. Where available and appropriate,  
40 pharmacogenomic testing can also be used to identify those at high risk of an ADR to guide  
41 medication choice, or optimal dose. Following initiation, management plans such as appropriate  
42 blood test monitoring and scheduled clinical review for ongoing indication can also reduce the risk of  
43 an ADR<sup>(24)</sup>. 29.4% of ADRs were possibly or probably caused by drug-drug interactions as per DIPS<sup>(18)</sup>.  
44 Deprescribing, defined as the process of dose-reduction or stopping of medicines by a healthcare  
45 professional, has been proposed as an important tool to reduce the burden of ADRs. The optimal  
46 use of medicines should include the entire prescribing spectrum including starting, dose-adjustment  
47 and stopping at the point at which harm outweighs benefit.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

## 58 **Comparison with Pirmohamed 2004**

1  
2  
3 Pirmohamed et al 2004<sup>(8)</sup> was a large prospective study of admission ADRs in two Liverpool  
4 hospitals, the large university teaching hospital used in this study and a smaller district general  
5 hospital. This found an ADR prevalence in hospital admissions of 6.5%, suggesting there has been a  
6 significant increase since 2004. Numerous clinical reasons could have influenced this including  
7 changes in population demographics, increased morbidity and prescribing patterns. Some of the  
8 increase may be because pharmacovigilance has improved over the last 20 years, and the adverse  
9 reaction profile of drugs is more comprehensive. For example, following a large case control study by  
10 Ernst et al<sup>(25)</sup>, an increased risk of pneumonia and dose dependant 30-day mortality from steroid  
11 based inhalers in COPD patients was added as a side effect to the British National Formulary. Over  
12 10% of the ADRs in this study are attributable to this. Some ADRs were also secondary to newer  
13 therapies including chemotherapies and monoclonal antibodies that have been developed since  
14 2004.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24 In 2004 two of the main causative medicines were NSAIDs (11.8%) and the antiplatelets (aspirin and  
25 clopidogrel) (23.8%). However, in this more recent study these medicines were implicated in only  
26 0.85% and 7.4% of the ADRs respectively. Despite the increase in total ADRs from 2004 this would  
27 suggest a large proportional reduction. This could be due to greater awareness of these ADRs in  
28 older people leading to enhanced pharmacovigilance in prescribers along with changes in prescribing  
29 practice including co-administration of proton pump inhibitors (PPI). However, this change has  
30 promoted PPIs as a cause of ADRs from very few cases to being responsible for 12.1% of ADRs in this  
31 study. The majority of the reactions were only mild transient electrolyte disturbances, with only a  
32 single severe associated ADR of *Clostridium difficile*. In the case of anti-platelets, two factors are  
33 likely to have contributed to this change: (a) there has been an active programme of reduction in  
34 their use for primary prevention of cardiovascular disease; and (b) changes in atrial fibrillation  
35 guidelines has led a greater use of anticoagulants rather than antiplatelets.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45 In recent years, concerns of an opiate crisis due to excessive community prescription has occurred in  
46 the USA<sup>(26)</sup>. In this study, opiate medications accounted for 5.1% of ADRs which is similar to the 6.0%  
47 found in 2004. This suggests that proportionally there has not been a significant increase in  
48 prescription opiate related admissions locally. Of the related 13 events, the majority were non-  
49 lethal, with only 2 cases exhibiting respiratory depression but with no permanent harm following  
50 reversal.

51  
52  
53  
54  
55  
56 Changes in prescribing patterns and subsequent ADRs may reflect increasing multimorbidity and  
57 polypharmacy. However, as such data was not previously collected this cannot be directly compared.  
58 Furthermore, methodological differences may have contributed as this study did not include any  
59  
60

1  
2  
3 data from a district general hospital or surgical admissions. Additionally, screening and data  
4 collection was completed by medical doctors and clinical pharmacologists, whereas previously it was  
5 completed by a number of healthcare professionals. Thus, differences in clinical and diagnostic  
6 experience could also be responsible for some increased identification of ADRs.  
7  
8  
9

### 10 **Multimorbidity and Polypharmacy**

11  
12  
13 Multimorbidity and polypharmacy were both associated with admission ADR on univariate analysis.  
14 Those with an ADR were taking on average 35% more medicines than those without (10.5 v 7.8, p  
15 <0.001), which is an established risk factor for ADRs<sup>(27)</sup>. Despite this polypharmacy must not be  
16 conflated with inappropriate prescribing as some patients, particularly those that are multimorbid,  
17 require multiple medicines to optimise their LTCs with associated positive outcomes. This study did  
18 not assess the appropriateness of all community prescriptions, but only of those that directly caused  
19 an ADR via the avoidability assessment tool.  
20  
21  
22  
23  
24  
25

26 The mean number of comorbidities for the entire admitted population was 5.4. Although we do not  
27 have direct data from 2004 for comparison it is reported that the incidence of multimorbidity has  
28 been increasing<sup>(2)</sup>. The ADR group on average had 17% more co-morbidities than the non-ADR group  
29 (6.1 vs 5.2, p<0.001), which is a known risk factor<sup>(27)</sup>. Although total number of co-morbidities is  
30 relevant, it does not to give insight into disease severity which may subsequently influence the  
31 number of medications a patient is taking. For example, hypertension or type 2 diabetes managed  
32 with lifestyle factors would produce less medication burden than more advanced disease.  
33  
34 Furthermore, some conditions and their management are known to predispose to prescribing  
35 cascades and therefore polypharmacy<sup>(27,28)</sup>. This may explain why the number of comorbidities was  
36 not significant following logistic regression analysis, with only age, number of medications and liver  
37 impairment being significant factors.  
38  
39  
40  
41  
42  
43  
44

### 45 **Cost analysis**

46  
47 ADRs are a significant cost burden on the NHS, and in this study accounted for £1 in every £8 spent  
48 on the care of non-elected hospital admissions. Put into perspective, the total cost of admissions  
49 related to ADRs over the 1-month study period (£490,716) is comparable with the annual cost of  
50 chemotherapy procurement by the hospital in which the study was conducted. When extrapolated  
51 nationally, our estimate of £2.21 billion for admissions resulting from ADRs exceeds the costs of all  
52 outpatient procedures for NHS England. Previous cost analyses of medication-related harm in  
53 England provide annual estimates of £1.9 billion based on an extrapolation from Pirmohamed et al  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (2004)<sup>(29)</sup>, £529m for potentially avoidable adverse drug reaction-related admissions <sup>(30)</sup>, and £396m  
4 for discharged elderly people <sup>(31)</sup>.  
5  
6

### 7 **Strengths and weaknesses**

8  
9  
10 Key strengths include that data was collected prospectively and notes were reviewed by specialists  
11 in clinical pharmacology and general internal medicine. This optimised the reliability of collected  
12 data and identification of ADRs. The availability of patient-level cost data, reflecting the actual spend  
13 on hospital care, represents another strength over many previous cost analyses.  
14  
15

16  
17 Using standardised criteria to identify and classify ADRs improves objectivity and reproducibility as  
18 evidenced by levels of concordance >90% between reviewers. However, some elements of the  
19 criteria can be subjective and rely on reviewer clinical experience. Furthermore, many of the medical  
20 conditions and side effects attributed to an ADR may have occurred regardless of prescription, for  
21 example regarding steroid inhalers and the increased risk of pneumonia in COPD patients. A  
22 limitation of our study is that we have not concurrently assessed the benefits of taking medicines in  
23 individual patients.  
24  
25

26  
27 It must be emphasised that causality assessment is a time-consuming process requiring clinical  
28 insight and therefore it is challenging to do this in time-limited real-world clinical practice. In the  
29 future, efforts to enhance the usability of electronic health care records, utilising time-saving  
30 approaches such as artificial intelligence and machine learning, could make medicines optimisation  
31 more efficient.  
32  
33

34  
35 Liverpool is ranked as the most deprived major city in England, an established factor in predicting  
36 increased morbidity <sup>(32)</sup>. With the disparity between the most and least deprived areas in England  
37 having increased since the 1990's <sup>(33)</sup>, changes in local population may have influenced differences  
38 found from 2004 as well as limit the utility of extrapolation of data nationally. In addition,  
39 generalisability of this data to more ethnically diverse populations is limited as Liverpool is 88%  
40 white<sup>(34)</sup>.  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **CONCLUSION**

51  
52 This study found ADRs contributed or directly caused 16.6% of all admissions with an associated  
53 mortality rate of 0.34%. Factors associated with an ADR on logistic regression included age, number  
54 of medications and liver impairment. The data suggests ADRs place a significant and increasing  
55 burden on patients and healthcare services with associated financial implications. Using patient-level  
56 cost data the projected annual cost of ADR admissions to the NHS in England is £2.21 billion. With  
57  
58  
59  
60

1  
2  
3 39.4% of these ADRs identified as avoidable or potentially avoidable future efforts should be  
4 directed to reduce this burden. Reducing inappropriate polypharmacy should be a major aim for  
5 preventing ADRs.  
6  
7

#### 8 9 Contributors statement

10  
11 Dr Rostam Osanlou undertook data collection, statistical analysis and wrote the initial draft of the  
12 paper. Dr Lauren Walker was involved in data collection, second reviewer and paper write up.  
13  
14 Professor Dyfrig Hughes undertook the cost analysis in this study and contributed to write up. Dr  
15  
16 Girvan Burnside undertook statistical analysis and contributed to paper write up. Professor Sir Munir  
17  
18 Pirmohamed came up with the idea, and was involved in assessing clinical cases and in reviewing the  
19  
20 initial drafts and final draft of the paper.  
21

#### 22 23 Funding

24  
25 MP receives research funding from various organisations including the MRC and NIHR. He has also  
26  
27 received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-  
28  
29 funded by MRC and Roche, UCB, Eli Lilly and Novartis); a PhD studentship jointly funded by EPSRC  
30  
31 and Astra Zeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted  
32  
33 educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from  
34  
35 Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but  
36  
37 does not benefit financially from this. He is part of the IMI Consortium ARDAT ([www.ardat.org](http://www.ardat.org)).  
38  
39 None of these of funding sources have been used for the current paper.

#### 40 41 Patient and public involvement

42  
43 The research question was developed due to the impact ADRs have on patients by causing  
44  
45 admissions to hospital. There were no patient contributors or co-authors in this study.

#### 46 47 Data sharing statement

48  
49 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
50  
51 all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis  
52  
53 to the BMJ Publishing Group Ltd ("BMJ"), and its Licencees to permit this article (if accepted) to be  
54  
55 published in The BMJ's editions and any other BMJ products and to exploit all subsidiary rights, as  
56  
57 set out in licence.

#### 58 59 Key messages bullet points

- 60
- Adverse drug reactions directly caused or contributed to 16.6% of all medical admissions



- Age, number of medications, multimorbidity, liver impairment and renal impairment are important factors associated with ADRs
- The cost of ADRs when extrapolated nationally may be as high as £2.21 billion per annum in England.

## Summary boxes

### *What we already know on this topic*

- In 2004 a large prospective study in the UK found adverse drug reactions accounted for 6.5% of hospital admissions
- Polypharmacy and multimorbidity are becoming increasingly prevalent in the UK population.

### *What this study adds*

- 16.6% of admissions directly or contributed by an ADR, a significant increase from 2004.
- The mortality attributable to adverse drug reactions was 0.34%.
- The projected annual financial cost to NHS in England is £2.1 billion
- Key associated factors included age, number of medications, multimorbidity, renal and hepatic impairment.

## References

1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]
2. Addressing the global challenge of multimorbidity, The Academy of Medical Sciences [Internet]. *Acmedsci.ac.uk*. 2020 [cited 15 December 2020]. Available from: <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity/evidence-submission>.
3. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol* 2012;22(17):R741-52. doi: 10.1016/j.cub.2012.07.024 [published Online First: 2012/09/15]
4. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017;17(1):230. doi: 10.1186/s12877-017-0621-2 [published Online First: 2017/10/12]
5. NHS Business Service Authority, Wessex Academic Health Science Network. (2017) Medicines Optimisation: Polypharmacy <https://www.nhsbsa.nhs.uk/epact2/epact2-dashboardsspecifications/medicinesoptimisation-polypharmacy>.
6. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. *BMC Med* 2015;13:74. doi: 10.1186/s12916-015-0322-7 [published Online First: 2015/04/19]
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998;279(15):1200-5. doi: 10.1001/jama.279.15.1200 [published Online First: 1998/04/29]
8. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 2004;329(7456):15-9. doi: 10.1136/bmj.329.7456.15 [published Online First: 2004/07/03]
9. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. *Drug Saf* 2015;38(5):437-53. doi: 10.1007/s40264-015-0281-0 [published Online First: 2015/03/31]
10. Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. *Bull Emerg Trauma* 2019;7(4):339-46. doi: 10.29252/beat-070401 [published Online First: 2019/12/21]
11. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in Scotland. *Pharm World Sci* 2008;30(6):854-62. doi: 10.1007/s11096-008-9240-5 [published Online First: 2008/07/26]
12. Bednall R, McRobbie D, Hicks A. Identification of medication-related attendances at an A & E department. *J Clin Pharm Ther* 2003;28(1):41-5. doi: 10.1046/j.0269-4727.2003.00461.x [published Online First: 2003/02/28]

- 1  
2  
3 13. Bps.ac.uk. 2016. The case for savings in the NHS. [online] Available at:  
4 <[https://www.bps.ac.uk/getmedia/8f24b222-b355-4f4a-8d91-f0a56190381e/The-case-for-savings-](https://www.bps.ac.uk/getmedia/8f24b222-b355-4f4a-8d91-f0a56190381e/The-case-for-savings-in-the-NHS-December-2016.pdf.aspx?ext=.pdf)  
5 [in-the-NHS-December-2016.pdf.aspx?ext=.pdf](https://www.bps.ac.uk/getmedia/8f24b222-b355-4f4a-8d91-f0a56190381e/The-case-for-savings-in-the-NHS-December-2016.pdf.aspx?ext=.pdf)> [Accessed 21 December 2021].  
6  
7  
8 14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet*  
9 2000;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9 [published Online First: 2000/11/10]  
10  
11 15. Davies DM, Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM,  
12 ed. Textbook of adverse drug reactions. Oxford: Oxford University Press,1991:18–45  
13  
14 16. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the  
15 Liverpool adverse drug reaction causality assessment tool. *PLoS One* 2011;6(12):e28096. doi:  
16 10.1371/journal.pone.0028096 [published Online First: 2011/12/24]  
17  
18 17. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse  
19 drug reactions. *Am J Hosp Pharm* 1992;49(9):2229-32. [published Online First: 1992/09/01]  
20  
21 18. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. *Ann*  
22 *Pharmacother* 2007;41(4):674-80. doi: 10.1345/aph.1H423 [published Online First: 2007/03/29]  
23  
24 19. Bracken LE, Nunn AJ, Kirkham JJ, et al. Development of the Liverpool Adverse Drug Reaction  
25 Avoidability Assessment Tool. *PLoS One* 2017;12(1):e0169393. doi: 10.1371/journal.pone.0169393  
26 [published Online First: 2017/01/04]  
27  
28 20. Joint Formulary Committee (2019) BNF 78: September 2019-March 2020. London:  
29 Pharmaceutical Press.  
30  
31 21. England, N., 2021. NHS England » National Cost Collection for the NHS. [online] England.nhs.uk.  
32 Available at: <<https://www.england.nhs.uk/national-cost-collection/#ncc1819>> [Accessed 4 January  
33 2021].  
34  
35 22. Patel PB, Patel TK. Mortality among patients due to adverse drug reactions that occur following  
36 hospitalisation: a meta-analysis. *Eur J Clin Pharmacol* 2019;75(9):1293-307. doi: 10.1007/s00228-  
37 019-02702-4 [published Online First: 2019/06/12]  
38  
39 23. Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse  
40 drug reactions and preventability of adverse drug reactions--a meta-analysis. *PLoS One*  
41 2012;7(3):e33236. doi: 10.1371/journal.pone.0033236 [published Online First: 2012/03/23]  
42  
43 24. Coleman JJ, Pontefract SK. Adverse drug reactions. *Clin Med (Lond)* 2016;16(5):481-85. doi:  
44 10.7861/clinmedicine.16-5-481 [published Online First: 2016/10/05]  
45  
46 25. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious  
47 pneumonia. *Thorax* 2013;68(11):1029-36. doi: 10.1136/thoraxjnl-2012-202872 [published Online  
48 First: 2013/10/17]  
49  
50 26. Chisholm-Burns MA, Spivey CA, Sherwin E, et al. The opioid crisis: Origins, trends, policies, and  
51 the roles of pharmacists. *Am J Health Syst Pharm* 2019;76(7):424-35. doi: 10.1093/ajhp/zxy089  
52 [published Online First: 2019/07/31]  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 27. Brath H, Mehta N, Savage RD, et al. What Is Known About Preventing, Detecting, and Reversing  
4 Prescribing Cascades: A Scoping Review. *J Am Geriatr Soc* 2018;66(11):2079-85. doi:  
5 10.1111/jgs.15543 [published Online First: 2018/10/20]  
6  
7  
8 28. Piggott KL, Mehta N, Wong CL, et al. Using a clinical process map to identify prescribing cascades  
9 in your patient. *BMJ* 2020;368:m261. doi: 10.1136/bmj.m261 [published Online First: 2020/02/23]  
10  
11 29. Compass. Adverse drug reactions wastes NHS £2BN reveals Compass. Compass; London; 2008.  
12 [Cited in <https://www.theguardian.com/society/2008/apr/03/nhs.drugsandalcohol>]  
13  
14  
15 30. National Institute for Health and Care Excellence. Costing statement: Medicines optimisation.  
16 Implementing the NICE guideline on medicines optimisation (NG5). March 2015.  
17 <https://www.nice.org.uk/guidance/ng5/resources/costing-statement-6916717>  
18  
19  
20 31. Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults  
21 following hospital discharge: a multicentre prospective study in the UK. *Br J Clin Pharmacol*  
22 2018;84(8):1789-97. doi: 10.1111/bcp.13613 [published Online First: 2018/05/24]  
23  
24  
25 32. English indices of deprivation 2019 [Internet]. GOV.UK; 2020 [cited 31 August 2020]. Available  
26 from: <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019>.  
27  
28  
29 33. Newton JN, Briggs AD, Murray CJ, et al. Changes in health in England, with analysis by English  
30 regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease  
31 Study 2013. *Lancet* 2015;386(10010):2257-74. doi: 10.1016/S0140-6736(15)00195-6 [published  
32 Online First: 2015/09/19]  
33  
34 34. Liverpool City Council. Demographics. March 2021. [https://liverpool.gov.uk/council/key-](https://liverpool.gov.uk/council/key-statistics-and-data/headline-indicators/demographics/)  
35 [statistics-and-data/headline-indicators/demographics/](https://liverpool.gov.uk/council/key-statistics-and-data/headline-indicators/demographics/) (accessed Dec 2021)  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables

**Table 1 – Drugs implicated in patient episodes with adverse drug reactions\***

Drug class	No of ADRs (%)	Offending drug	ADR
Diuretics	31 (14.2%)	Furosemide (13), pironolactone (8), bumetanide (6), bendroflumethiazide (2), coamilofruse (1), indapamide (1)	Renal impairment (18), electrolyte derangement (12), postural hypotension (1)
Steroid inhaler	27 (12.4%)	Steroid inhaler (27)	Pneumonia (26), Oral Thrush (1)
Anticoagulants	21 (9.6%)	Warfarin (7), apixaban (5), edoxaban (4), rivaroxaban (4), enoxaparin (1)	Minor bleeding (10), anaemia (4), intracranial haemorrhage (4), Gastrointestinal bleed (3)
Proton pump inhibitor	18 (8.3%)	Lansoprazole (9), omeprazole (6), pantoprazole (3)	Hypomagnesaemia (11), hyponatraemia (6), C.Diff (1)
Antiplatelet	16 (7.4%)	Aspirin (13), clopidogrel (3)	Intracranial haemorrhage (5), Gastrointestinal bleed (4), minor bleeding (4), anaemia
Chemotherapy	16 (7.3%)	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Deranged electrolytes (1), Rash (1), Thrombocytopenia (1)
ACE <sup>(1)</sup> -inhibitor / angiotensin receptor blocker	14 (6.4%)	Losartan (4), ramipril (4), irbesartan (3), candesartan (1), lisinopril (1), perindopril (1)	Renal impairment (9), postural hypotension (3), hyperkalaemia (1), renal failure (1)
Antidepressants & Antipsychotics	13 (6.0%)	Mirtazapine (2), sertraline (2), sulpride (2), carbamazepine (1), dosulepin (1), nortriptyline (1), olanzapine (1), risperidone (1)	Confusion (3), hyponatraemia (3), parkinsonism (3), constipation (1), gastrointestinal bleed (1), prolonged QTc <sup>(2)</sup> (1)
Opiates	13 (6.0%)	Codeine (5), morphine sulphate (3), oxycodone (2), tramadol (2), buprenorphine (1)	Constipation (6), confusion (4), respiratory depression (2), hallucinations (1)
Other	49 (22.4%)	Other (49)	Other (49)

<sup>(1)</sup> Angiotensin converting enzyme <sup>(2)</sup> Corrected QT interval  
 \*In those with multiple ADRs only the most severe ADR was included in this table, as defined by the adapted Hartwig severity scale <sup>(16)</sup>. See supplementary material for full list.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 2– Deaths directly related to the adverse reaction (Adapted Hartwig class 7b)**

Medication	Number	Cause of death
Chemotherapy	2	Neutropenic sepsis (2)
Aspirin	1	Intracranial haemorrhage
Edoxaban	1	Gastrointestinal bleed

For peer review only

**Table 3 – Characteristics of patients with and without adverse drug reactions**

	ADR <sup>(1)</sup> group	Non ADR group	Total
<b>Number of admissions</b>	218	969	1187
<b>Age</b>			
Mean (s.d.)	73.2 (14.5)	66.7 (19.2)	67.9 (18.6)
<b>Male (%)</b>	106 (48.6%)	455 (47.0%)	561 (47.3%)
<b>Number of medicines</b>			
Mean (s.d.)	10.5 (4.6)	7.8 (5.1)	8.3 (5.1)
<b>Polypharmacy (%)</b>	199 (91.3%)	706 (72.9%)	905 (76.2%)
<b>Number of co-morbidities</b>			
Mean (s.d.)	6.1 (3.0)	5.2 (3.3)	5.4 (3.2)
<b>Multimorbid (%)</b>	99.1%	90.3%	91.9%
<b>Liver impairment * (%)</b>	6.9%	2.8%	3.5%
<b>Renal impairment ** (%)</b>	11.0%	6.8%	7.6%
<sup>(1)</sup> Adverse drug reation			
* Liver impairment defined as Chronic Liver Disease			
** Renal impairment defined as Chronic Kidney Disease stage IV or V			



**Table 4: Logistic regression analysis of patients with and without adverse drug reactions**

	<b>Univariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>	<b>Multivariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>
<b>Age</b>	1.02 (1.01, 1.03)	<0.001	1.02 (1.01, 1.03)	<0.001
<b>Sex (Male)</b>	1.07 (0.80, 1.44)	0.659		
<b>Number of medicines</b>	1.11 (1.07, 1.14)	<0.001	1.10 (1.07, 1.13)	<0.001
<b>Number of comorbidities</b>	1.08 (1.04, 1.13)	<0.001		
<b>Liver impairment (CLD)</b>	2.58 (1.35, 4.93)	0.004	3.23 (1.63, 6.40)	<0.001
<b>Renal impairment (CKD stage 4 or 5)</b>	1.69 (1.04, 2.78)	0.036		

## Supplementary material - Full list of Adverse reactions by drug class

Drug Class	Number of associated ADRs	Medications implicated	Adverse reaction
<b>Diuretics</b>	31	Furosemide (13), Spironolactone (8), Bumetanide (6), Bendroflumethiazide (2), Coamilofruse (1), Indapamide (1)	Renal impairment (18), Electrolyte derrangement (12), Postural hypotension (1)
<b>Steroid inhaler</b>	27	Steroid inhaler (27)	CAP (26), Oral Thrush (1)
<b>Anticoagulants</b>	21	Warfarin (7), Apixaban (5), Edoxaban (4), Rivaroxaban (4), Enoxaparin (1)	Minor bleeding (10), Anaemia (4), Intracranial haemorrhage (4), GI bleed (3)
<b>Proton Pump Inhibitor</b>	18	Lansoprazole (9), Omeprazole (6), Pantoprazole (3)	Hypomagnasaemia (11), Hyponatraemia (6), C.Diff (1)
<b>Antiplatelets</b>	16	Aspirin (13), Clopidogrel (3)	Intracranial haemorrhage (5), GI bleed (4), Minor bleeding (4), Anaemia
<b>Chemotherapy</b>	16	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Derranged electrolytes (1), Rash (1), Thrombocytopenia (1)
<b>ACE-I <sup>(1)</sup> /ARB <sup>(2)</sup></b>	14	Losartan (4), Ramipril (4), Irbesartan (3), Candesartan (1), Lisinopril (1), Perindopril (1)	Renal impairment (9), Postural hypotension (3), Hyperkalaemia (1), Renal failure (1)
<b>Antidepressants &amp; antipsychotics</b>	13	Mirtazapine (2), Sertraline (2), Sulpride (2), Carbamazepine (1), Dosulepin (1), Nortriptyline (1), Olanzapine (1), Risperidone (1)	Confusion (3), Hyponatraemia (3), Parkinsonism (3), Constipation (1), GI bleed (1), Prolonged QTc (1)
<b>Opiates</b>	13	Codeine (5), Morphine Sulphate (3), Oxycodone (2), Tramadol (2), Buprenorphine (1)	Constipation (6), Confusion (4), Respiratory Depression (2), Hallucinations (1)
<b>Beta adrenoceptor blockers</b>	9	Bisoprolol (6), Atenolol (1), Nebivolol (1), Propranolol (1)	Bradycardia (5), Postural hypotension (4)
<b>Insulin</b>	7	Insulin (7)	Hypoglycaemia (4), Hypoglycaemic seizures (2)
<b>Calcium Channel Blocker</b>	6	Amlodipine (4), Ivabradine (1), Diltiazem (1)	Postural hypotension (5), Prolonged QTc (1)
<b>Bladder anticholinergics</b>	6	Solifenacin (4), Tolterodine (1), Tropsium (1)	Confusion (4), Constipation (2)
<b>Immunosuppressants</b>	5	MMF (3), Tacrolimus (2)	Sepsis (5)
<b>Antimicrobials</b>	4	Penicillin (2), Aciclovir (1), Azithromycin (1)	Angioedema (1), Rash (1), Renal impairment (1), Prolonged QTc (1)

<b>Oral anti diabetics</b>	4	Gliclazide (2), Empagliflozin (1), Pioglitazone (1)	Hypoglycaemia (2), Heart Failure (1), Urinary Tract infection (1)
<b>Monoclonals</b>	3	Afatanib (1), Pembrolizumab (1), Ruxolitinib (1)	Liver toxicity (1), Pneumonitis (1), Sepsis (1)
<b>Statins</b>	2	Atorvastatin (1), Simvastatin (1)	Myopathy (2)
<b>Levodopa</b>	2	Co-beneldopa (1), Co-careldopa (1)	Postural Hypotension (2)
<b>PTH<sup>(3)</sup> analogues</b>	2	Alfacalcidol (1), Calcitriol (1)	Hypercalcaemia (2)
<b>NSAIDs<sup>(4)</sup></b>	2	Naproxen (2)	ACS (1), GI Bleed (1)
<b>Benzodiazepines</b>	2	Lorazepam (1), Tempazepam (1)	Confusion (2)
<b>Baclofen</b>	1	Baclofen (1)	Constipation (1)
<b>Amitriptyline</b>	1	Amitriptyline (1)	Confusion (1)
<b>Leviteracitem</b>	1	Leviteracitem (1)	Renal impairment (1)
<b>Doxazocin</b>	1	Doxazocin (1)	Postural hypotension (1)
<b>Nefopam</b>	1	Nefopam (1)	Delirium (1)
<b>Quinine</b>	1	Quinine (1)	Prolonged QTc (1)
<b>Lithium</b>	1	Lithium (1)	Lithium Toxicity (1)
<b>Laxatives</b>	1	Laxatives (1)	Diarrhoea (1)
<b>Bisphosphonates</b>	1	Alendronic Acid (1)	Erosive Gastritis (1)
<b>Thyroxine</b>	1	Levothyroxine (1)	Tachyarrhythmia (1)
<b>Zopiclone</b>	1	Zopiclone (1)	Confusion (1)
<b>Phosphodiesterase inhibitor</b>	1	Uniphyllin (1)	Nausea (1)

(1) Angiotensin converting enzyme inhibitor (2) Angiotensin receptor blocker (3) Parathyroid hormone (4) Non steroidal anti inflammatory

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	4
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	4
		(e) Describe any sensitivity analyses	n/a

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	4
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	16
		(b) Indicate number of participants with missing data for each variable of interest	4
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16
		(b) Report category boundaries when continuous variables were categorized	16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Table 4
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Additional

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055551.R2
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2022
Complete List of Authors:	Osanlou, Rostam; University of Liverpool, Department of Pharmacology and Therapeutics; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Pharmacology and Therapeutics Walker, Lauren; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics Hughes, Dyfrig; Bangor University, Centre for Health Economics and Medicines Evaluation Burnside, Girvan; University of Liverpool, Department of Biostatistics Pirmohamed, Munir; University of Liverpool, Department of Pharmacology and Therapeutics; Liverpool University Hospital Foundation NHS Trust, Department of Pharmacology and Therapeutics
<b>Primary Subject Heading</b>:	Pharmacology and therapeutics
Secondary Subject Heading:	Health economics
Keywords:	Adverse events < THERAPEUTICS, CLINICAL PHARMACOLOGY, HEALTH ECONOMICS, INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Adverse drug reactions, multimorbidity and polypharmacy: A prospective analysis of one month of medical admissions

Rostam Osanlou<sup>1,2</sup>, Lauren Walker<sup>1,2</sup>, Dyfrig Hughes<sup>3</sup>, Girvan Burnside<sup>4</sup>, Munir Pirmohamed<sup>1,2</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE

<sup>2</sup>Liverpool University Hospital Foundation NHS Trust, Prescot Street, Liverpool, L7 8XP

<sup>3</sup>Centre for health economics and medicines evaluation, University of Bangor, College Road, Bangor LL57 2DG

<sup>4</sup>Department of Biostatistics, University of Liverpool, Liverpool L69 3GE

Author for correspondence:

Prof M Pirmohamed  
Institute of Systems, Molecular and Integrative Biology (ISMIB)  
University of Liverpool  
Block A: Waterhouse Building  
1-5 Brownlow Street  
Liverpool L69 3GL  
[munirp@liverpool.ac.uk](mailto:munirp@liverpool.ac.uk)

**Word count:** 3327

**Keywords:** Adverse drug reaction, ADR, Multimorbidity, Polypharmacy



## ABSTRACT

**Objective** To ascertain the burden and associated cost of adverse drug reactions (ADRs), polypharmacy and multimorbidity through a prospective analysis of all medical admissions to a large University teaching hospital over a one-month period.

**Design** Prospective observational study.

**Setting** Liverpool University Hospital Foundation NHS Trust, England.

**Participants** All medical admissions with greater than 24-hour stay over a one-month period.

**Main outcome measures** Prevalence of admissions due to an ADR and associated mortality. Prevalence and association of multimorbidity and polypharmacy with ADRs. Estimated local financial cost of admissions where ADR was a contributing or main reason for admission with projected costs for NHS in England.

**Results** There were 218 identified patient admissions with an ADR giving a prevalence of 18.4%. The majority of these (90.4%) were ADRs that directly resulted in or contributed to admission. ADRs thus accounted for 16.5% of total admissions. Those with an ADR were on average taking more medicines (10.5 vs 7.8  $p<0.01$ ) and had more co-morbidities than those without an ADR (6.1 vs 5.2,  $p<0.01$ ). Drugs most commonly implicated were diuretics, steroid inhalers, anticoagulants & antiplatelets, proton pump inhibitors, chemotherapeutic agents and antihypertensives. 40.4% of ADRs were classified avoidable or possibly avoidable. The mortality rate due to an ADR was 0.34%. The average length of stay for those with an ADR was 6 days. Direct one month cost to the Trust from ADR admissions was £490,716. Extrapolated nationally the projected annual cost to the NHS in England is 2.21 billion.

**Conclusion** The local prevalence of admission and mortality from ADRs are higher than previously reported. Important factors that could be contributing to this include polypharmacy and multimorbidity. ADRs place a significant burden on patients and healthcare services with associated financial implications. Reducing inappropriate polypharmacy should be a major aim for preventing ADRs.

**Strengths and limitations of this study:**

- Over 1000 medical admissions were individually reviewed by specialists in clinical pharmacology and general internal medicine in this prospective analysis of adverse drug reactions.
- Standardised criteria, as listed in methods, were used to identify and classify ADRs. This improves the objectivity and reproducibility of the analysis.
- Extrapolating the cost analysis nationally based on medical admissions locally may be unreliable due to differences including local population and services.
- This study does not take into account how commonly each medicine that caused an ADR is prescribed in the local community.

## INTRODUCTION

Improved living conditions, and better access to and quality of medical care, has led to increased life expectancy and the associated accumulation of Long Term Conditions (LTC) <sup>(1)</sup>. According to a report by the Academy of Medical Sciences, multimorbidity is a growing issue globally, particularly in more economically developed countries where it is now considered the norm not the exception <sup>(2)</sup>. Age is the single biggest risk factor for LTCs such as cancer, cardiovascular disease and neurodegeneration in developed countries. An ageing population is therefore at increased risk of polypharmacy <sup>(3)</sup>. Care for people with multiple LTCs is often stretched across various single-organ specialists leading to siloed specialty prescribing and increasingly complex medication regimens.

Polypharmacy is the concurrent use of multiple medications by an individual. There is no consensus on the number of medications that defines polypharmacy because of the need to treat complex or multiple comorbidities with combinations of medicines. Thus, numerical definitions vary but perhaps the most common definition is taking 5 or more regular medications <sup>(4)</sup>. The Wessex Academic Health Science Network have developed a set of prescribing comparators to better understand both the numerical and risk-related factors involved in the variation of prescribing of multiple medicines <sup>(5)</sup>. In some individuals with complex or multiple conditions, polypharmacy may be appropriate, for example when medicines use has been individually optimised and prescribed according to best evidence. In contrast, potentially inappropriate polypharmacy, wherein the risk of harms from individual medicines may outweigh their benefit in the context of the prescription as a whole, is associated with poor adherence and an increased risk of adverse-drug reactions (ADRs) and interactions <sup>(6)</sup>. ADRs are an important cause of morbidity and mortality, with significant health implications and associated economic burden. Landmark studies in the USA in 1998 <sup>(7)</sup> and the UK in 2004 <sup>(8)</sup> found ADRs to be related to 6.7% and 6.5% of hospital admissions, respectively. More recent systematic reviews have reported figures ranging from 3.6% <sup>(9)</sup> to 15.6% <sup>(10)</sup>. Potential reasons for variation in findings include the heterogeneity of methodologies and populations studied.

Addressing avoidable ADRs due to inappropriate prescribing is important to reduce the burden on patients and healthcare systems. There are few adult observational studies of admission ADRs in the United Kingdom that are not focused on a specific populations or drug reactions. To our knowledge there are only 3 in the last 20 years <sup>(8,11,12)</sup>. In 2016, it was estimated that £1.3-3 billion could be saved in the NHS budget through reducing inappropriate and inefficient medicines usage <sup>(13)</sup>.

The aim of this study was to determine the current impact of ADRs on medical admissions, their association with multimorbidity and polypharmacy, and quantify the economic impact on the

1  
2  
3 National Health Service (NHS). The population studied is broadly geographically comparable to that  
4 of Pirmohamed et al 2004 <sup>(8)</sup>.  
5  
6  
7  
8  
9

## 10 METHODS

11  
12 Study data was collected for one month in the city centre site of the Liverpool University Hospital  
13 Foundation NHS Trust, a large teaching hospital in Merseyside, England. The research question was  
14 developed due to the impact ADRs have on patients by causing admissions to hospital. There were  
15 no patient contributors or co-authors in this study. Approval for this study was granted by Liverpool  
16 University Hospital Foundation NHS Trust clinical audit and service evaluation department (Project  
17 number 7580). All patients referred via the medical assessment unit that were admitted for >24  
18 hours were included. These were mostly via the emergency department but also included primary  
19 care referrals and admissions from outpatient clinics. Patients admitted via medicine but transferred  
20 to other centres for emergency treatment (such as primary coronary intervention) within 24 hours  
21 were included, as their expected inpatient stay would be >24 hours. Information including e-notes,  
22 community drug prescriptions and investigations were reviewed to determine if an ADR occurred.  
23 An ADR was defined using the Edwards and Aronson criteria <sup>(14)</sup>. This does not include any type of  
24 drug overdose or relapse due to noncompliance. Cases were then defined as either the primary  
25 cause of admission, contributing factor or a co-incidental finding and assessed against the following  
26 criteria:  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

- 38 • Classification of the reaction as per Rawlins and Thompson <sup>(15)</sup> into Type A or Type B  
39 reactions.
- 40 • Causality as per the Liverpool causality assessment tool (LCAT) <sup>(16)</sup>. This is a validated  
41 method of assessing the causality of ADRs that can be used by groups or individuals.
- 42 • Severity as per the adapted Hartwig severity scale (AHSS) <sup>(17)</sup>, a widely used tool that  
43 categorises ADRs from severity level 1 (requires no change in treatment) to level 6  
44 (directly or indirectly resulted in patient death).
- 45 • Interactions as per the drug interaction probability scale (DIPS) <sup>(18)</sup>. DIPS assists  
46 practitioners in the assessment of drug interaction and evaluating causation in a specific  
47 patient.
- 48 • Avoidability as per the Liverpool ADR avoidability assessment tool (LAAT) <sup>(19)</sup>. This is a  
49 validated a tool to support the assessment of the avoidability of ADRs based on available  
50 patient information.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Factors that suggested an ADR include if it was consistent with the known adverse effect profile of  
4 the drug as per the British National Formulary <sup>(20)</sup>, if there was a temporal relationship, and if  
5 alternate causes were excluded with history and investigation. Community drug prescription were  
6 verified and reviewed with patient electronic notes. This data was available for all admitted patients.  
7  
8 If it was documented in the notes that a patient was not taking a medicine listed on their  
9 prescription this was not included in our analysis.  
10  
11  
12

13  
14 Identification of ADRs and subsequent assessment of the above criteria was completed by authors  
15 RO and LW. Where consensus was not reached it was assessed by third reviewer MP. Of the 258  
16 patient episodes with possible identified ADRs, there was initial agreement on 236 (91%). For the  
17 remainder consensus was obtained following joint review with MP.  
18  
19  
20

21 Patient Level Information and Costing System (PLICS) data reporting healthcare resource group and  
22 hospital costs were obtained from the Liverpool University Hospitals NHS Foundation Trust finance  
23 office. Total costs were summed for episodes of admitted care resulting from ADRs (a), and for all  
24 other admissions (where ADR was a contributory factor, coincidental, or unrelated; (b)). In order to  
25 extrapolate costs, totals for non-elective short and long stay, and regular day or night admissions, for  
26 NHS England (c), were obtained for 2018-19 <sup>(21)</sup>. Nationally projected costs were estimated as  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
 $(a.c)/(a+b)$ .

### **Patient and public involvement**

The research question was developed due to the impact ADRs have on patients by causing admissions to hospital. There were no patient contributors or co-authors in this study.

### **STATISTICAL ANALYSIS**

Statistical analysis was performed using the SAS software (Version 9.4, SAS Institute, Cary, NC, USA). The results are presented either as means and standard deviations or frequencies and percentages. Associations between patient characteristics and admission type (ADR/Non-ADR) were investigated using univariable and multivariable logistic regression, with associations presented as odds ratios (OR) with 95% confidence intervals. The multivariable model used backwards selection with a probability of exclusion of 0.1. A P value < 0.05 was regarded as statistically significant.

### **RESULTS**

1  
2  
3 There were 1,187 admissions with 218 patients with an ADR (18.4%). As some of those had multiple  
4 ADRs 235 were identified in total.  
5  
6

### 7 **Characteristics of adverse drug reactions**

8  
9 145 (66.5%) of the ADRs were the primary cause of admission, with 51 (23.4%) contributing to  
10 admission, and 22 (10.1%) co-incident findings that alone would not have required hospital stay.  
11 Thus, ADRs directly caused or contributed to 16.5% of all admissions. Using the Liverpool causality  
12 assessment tool <sup>(16)</sup> 45 (20.6%) were graded as definite, 79 (36.2%) as probable, and 94 (43.1%) as  
13 possible ADRs. 40 (18.4%) were graded as avoidable and 46 (21.1%) as possibly avoidable using LAAT  
14 criteria <sup>(19)</sup>. 64 (29.4%) of ADRs were possibly or probably cause by a drug-drug interaction as per  
15 DIPS <sup>(18)</sup>. 188 (86.2%) were Type A reactions as defined by Rawlins and Thompson <sup>(15)</sup> and 30 (13.8%)  
16 Type B. 164 (75.2%) of the ADRs were documented as recognised or acted on by the admitting  
17 medical team. The main drugs implicated in ADRs are listed in table 1. There were 4 ADRs (1.8%)  
18 that directly resulted in death and a further 5 that were implicated or a contributing factor to death  
19 (2.3%) (table 2). The mortality rate directly from ADRs, from all admissions, was therefore 0.42%.  
20 Median length of stay of patients with an ADR was 6 days.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Comparison of patients with and without adverse drug reactions**

31  
32 Table 3 shows descriptive statistics of patients with and without ADRs. In the patients with ADRs, as  
33 would be expected. liver and renal impairment were more prevalent compared to patients without  
34 ADRs (6.8% vs 2.8%, p 0.004),  
35  
36  
37

38 Logistic regression results are presented in Table 4. Patients with ADRs were older than those  
39 without (mean age 73.2 (14.5) vs 66.7 (19.2), OR 1.02 (1.01, 1.03)) and were taking more medicines  
40 (mean 10.5 (4.6) vs 7.8 (5.1), OR 1.11 (1.07, 1.14)), with polypharmacy present in 91%, compared to  
41 73% in the non-ADR group. They had more comorbidities (mean 6.1 (3.0) vs 5.2 (3.3), OR 1.08 (1.04,  
42 1.13)), although this variable was not included in the multivariable model (due to its correlation with  
43 number of medicines). Those with ADRs were more likely to have liver impairment (6.9% vs 2.8%, OR  
44 2.58 (1.35, 4.93)) and renal impairment (11.0% vs 6.8%, OR 1.69 (1.04, 2.78).  
45  
46  
47  
48  
49  
50

51 HRG costs were available for 214 (98.2%) patients in the ADR group, and 950 (98.0%) patients in the  
52 non-ADR group. Mean costs per episode of care were £2,293 (95% CI 1918, 2668) and £2,131 (95%  
53 CI 1899, 2364), respectively. The total costs of admissions resulting from ADR were £309,207,  
54 representing 12.3% of the costs of the whole cohort over the 1-month sampling frame. Admissions  
55 where ADR was a contributory factor cost £138,762 (5.5%); and where ADR was coincidental, the  
56 cost was £42,747 (1.7%). The total costs of non-elective short and long stays, and regular day or  
57  
58  
59  
60

1  
2  
3 night admissions across all NHS trusts and NHS foundation trusts in England was £17.98 bn in 2018-  
4  
5 19, of which we estimate £2.21 bn were due to admissions resulting from ADRs.  
6  
7  
8  
9

## 10 DISCUSSION

11  
12 This study found ADRs in 18.4% of hospital admissions. In 16.5% of admissions, it was the primary  
13 cause or a contributing cause suggesting ADRs have a significant burden on hospital admissions. This  
14 is over twice as high as the 6.5% found in Pirmohamed 2004 <sup>(8)</sup> which consisted of broadly the same  
15 geographical area. Most commonly implicated medicines included diuretics, steroid based inhalers,  
16 anticoagulants, proton pump inhibitors, antiplatelets, chemotherapy agents, anti-hypertensives,  
17 opiates and antidepressants/antipsychotics (Table 1). It is important to consider this study does not  
18 reflect how often each of these medicines are prescribed in the community. Some of the medicines  
19 implicated with the highest number of ADRs and deaths may be a reflection of how commonly they  
20 are prescribed. Furthermore, the use of these medicines also provides clinical benefits that reduce  
21 morbidity, mortality and need for hospital admissions, and this is not taken into account by our data.  
22 Direct mortality from ADRs was 0.42% which is also an increase from Pirmohamed 2004 (0.15%) <sup>(8)</sup>  
23 and twice as high as a recent meta-analysis <sup>(22)</sup>.  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Approximately, 40% of ADRs were classified as avoidable or possibly avoidable. This is consistent  
34 with previous studies which found significant proportions of ADRs that lead to hospital admissions  
35 are potentially avoidable <sup>(23)</sup>. Furthermore, as expected, the majority (86.2%) of ADRs were 'Type A'  
36 reactions meaning that they were the result of the expected pharmacological action of the medicine  
37 and therefore potentially more predictable and avoidable. Given this, future efforts should be  
38 targeted at reducing these preventable admissions. Key strategies that can mitigate for ADRs include  
39 stratifying patients by susceptibility prior to medication initiation using key information such as co-  
40 morbidities, concomitant medications and renal and hepatic function. This is particularly required in  
41 elderly patients who are at risk of accumulating multiple age-related health deficiencies that require  
42 drug therapy <sup>(24)</sup>. Where available and appropriate, pharmacogenomic testing can also be used to  
43 identify those at high risk of an ADR to guide medication choice, or optimal dose. Following  
44 initiation, management plans such as appropriate blood test monitoring and scheduled clinical  
45 review for ongoing indication can also reduce the risk of an ADR <sup>(25)</sup>. 29.4% of ADRs were possibly or  
46 probably caused by drug-drug interactions as per DIPS <sup>(18)</sup>. Deprescribing, defined as the process of  
47 dose-reduction or stopping of medicines by a healthcare professional, has been proposed as an  
48 important tool to reduce the burden of ADRs. The optimal use of medicines should include the  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

entire prescribing spectrum including starting, dose-adjustment and stopping at the point at which harm outweighs benefit.

#### Comparison with Pirmohamed 2004

Pirmohamed et al 2004<sup>(8)</sup> was a large prospective study of admission ADRs in two Liverpool hospitals, the large university teaching hospital used in this study and a smaller district general hospital. This found an ADR prevalence in hospital admissions of 6.5%, suggesting there has been a significant increase since 2004. Numerous clinical reasons could have influenced this including changes in population demographics, increased morbidity and prescribing patterns. Some of the increase may be because pharmacovigilance has improved over the last 20 years, and the adverse reaction profile of drugs is more comprehensive. For example, following a large case control study by Ernst et al<sup>(26)</sup>, an increased risk of pneumonia and dose dependant 30-day mortality from steroid based inhalers in COPD patients was added as a side effect to the British National Formulary. Over 10% of the ADRs in this study are attributable to this. Some ADRs were also secondary to newer therapies including chemotherapies and monoclonal antibodies that have been developed since 2004.

In 2004 two of the main causative medicines were NSAIDs (11.8%) and the antiplatelets (aspirin and clopidogrel) (23.8%). However, in this more recent study these medicines were implicated in only 0.85% and 7.4% of the ADRs respectively. Despite the increase in total ADRs from 2004 this would suggest a large proportional reduction. This could be due to greater awareness of these ADRs in older people leading to enhanced pharmacovigilance in prescribers along with changes in prescribing practice including co-administration of proton pump inhibitors (PPI). However, this change has promoted PPIs as a cause of ADRs from very few cases to being responsible for 12.1% of ADRs in this study. The majority of the reactions were only mild transient electrolyte disturbances, with only a single severe associated ADR of *Clostridium difficile*. In the case of anti-platelets, two factors are likely to have contributed to this change: (a) there has been an active programme of reduction in their use for primary prevention of cardiovascular disease; and (b) changes in atrial fibrillation guidelines has led a greater use of anticoagulants rather than antiplatelets.

In recent years, concerns of an opiate crisis due to excessive community prescription has occurred in the USA<sup>(27)</sup>. In this study, opiate medications accounted for 5.1% of ADRs which is similar to the 6.0% found in 2004. This suggests that proportionally there has not been a significant increase in prescription opiate related admissions locally. Of the related 13 events, the majority were non-



1  
2  
3 lethal, with only 2 cases exhibiting respiratory depression but with no permanent harm following  
4 reversal.  
5

6  
7 Changes in prescribing patterns and subsequent ADRs may reflect increasing multimorbidity and  
8 polypharmacy. However, as such data was not previously collected this cannot be directly compared.  
9 Furthermore, methodological differences may have contributed as this study did not include any  
10 data from a district general hospital or surgical admissions. Additionally, screening and data  
11 collection was completed by medical doctors and clinical pharmacologists, whereas previously it was  
12 completed by a number of healthcare professionals. Thus, differences in clinical and diagnostic  
13 experience could also be responsible for some increased identification of ADRs. Finally, since 2004  
14 Liverpool University Hospital Foundation NHS Trust has adopted electronic health records which  
15 may have assisted in the identification of ADRs in this study.  
16  
17  
18  
19  
20  
21

### 22 23 **Multimorbidity and Polypharmacy**

24  
25 Multimorbidity and polypharmacy were both associated with admission ADR on univariate analysis.  
26 Those with an ADR were taking on average 35% more medicines than those without (10.5 v 7.8,  $p$   
27  $<0.001$ ), which is an established risk factor for ADRs<sup>(28)</sup>. Despite this polypharmacy must not be  
28 conflated with inappropriate prescribing as some patients, particularly those that are multimorbid,  
29 require multiple medicines to optimise their LTCs with associated positive outcomes. This study did  
30 not assess the appropriateness of all community prescriptions, but only of those that directly caused  
31 an ADR via the avoidability assessment tool.  
32  
33  
34  
35  
36

37  
38 The mean number of comorbidities for the entire admitted population was 5.4. Although we do not  
39 have direct data from 2004 for comparison it is reported that the incidence of multimorbidity has  
40 been increasing<sup>(2)</sup>. The ADR group on average had 17% more co-morbidities than the non-ADR group  
41 (6.1 vs 5.2,  $p<0.001$ ), which is a known risk factor<sup>(28)</sup>. However, the number of comorbidities was  
42 not part of the logistic regression because of the correlation between the number of medicines and  
43 number of co-morbidities. Although total number of co-morbidities is relevant, it does not to give  
44 insight into disease severity, for which the number of medications being taken may be a better  
45 proxy. For example, hypertension or type 2 diabetes managed with lifestyle factors would produce  
46 less medication burden than more advanced disease. Furthermore, some conditions and their  
47 management are known to predispose to prescribing cascades and therefore polypharmacy<sup>(28,29)</sup>.  
48  
49  
50  
51  
52  
53  
54  
55

### 56 **Cost analysis**

57  
58 ADRs are a significant cost burden on the NHS, and in this study accounted for £1 in every £8 spent  
59 on the care of non-elected hospital admissions. Put into perspective, the total cost of admissions  
60

1  
2  
3 related to ADRs over the 1-month study period (£490,716) is comparable with the annual cost of  
4 chemotherapy procurement by the hospital in which the study was conducted. When extrapolated  
5 nationally, our estimate of £2.21 bn for admissions resulting from ADRs exceeds the costs of all  
6 outpatient procedures for NHS England. Previous cost analyses of medication-related harm in  
7 England provide annual estimates of £1.9 bn based on an extrapolation from Pirmohamed et al  
8 (2004)<sup>(30)</sup>, £529m for potentially avoidable adverse drug reaction-related admissions<sup>(31)</sup>, and £396m  
9 for discharged elderly people<sup>(32)</sup>.

### 16 **Strengths and weaknesses**

17  
18 Key strengths include that data was collected prospectively and notes were reviewed by specialists  
19 in clinical pharmacology and general internal medicine. This optimised the reliability of collected  
20 data and identification of ADRs. The availability of patient-level cost data, reflecting the actual spend  
21 on hospital care, represents another strength over many previous cost analyses.  
22  
23

24  
25 Using standardised criteria to identify and classify ADRs improves objectivity and reproducibility as  
26 evidenced by levels of concordance >90% between reviewers. However, some elements of the  
27 criteria can be subjective and rely on reviewer clinical experience. Furthermore, many of the medical  
28 conditions and side effects attributed to an ADR may have occurred regardless of prescription, for  
29 example regarding steroid inhalers and the increased risk of pneumonia in COPD patients. A  
30 limitation of our study is that we have not concurrently assessed the benefits of taking medicines in  
31 individual patients.  
32  
33

34  
35 It must be emphasised that causality assessment is a time-consuming process requiring clinical  
36 insight and therefore it is challenging to do this in time-limited real-world clinical practice. In the  
37 future, efforts to enhance the usability of electronic health care records, utilising time-saving  
38 approaches such as artificial intelligence and machine learning, could make medicines optimisation  
39 more efficient.  
40  
41

42  
43 Liverpool is ranked as the most deprived major city in England, an established factor in predicting  
44 increased morbidity<sup>(32)</sup>. With the disparity between the most and least deprived areas in England  
45 having increased since the 1990's<sup>(33,34)</sup>, changes in local population may have influenced differences  
46 found from 2004 as well as limit the utility of extrapolation of data nationally. In addition,  
47 generalisability of this data to more ethnically diverse populations is limited as Liverpool is 91%  
48 white.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

This study found ADRs contributed or directly caused 16.5% of all admissions with an associated mortality rate of 0.34%. Factors associated with an ADR on logistic regression included age, number of medications and liver impairment. The data suggests ADRs place a significant and increasing burden on patients and healthcare services with associated financial implications. Using patient-level cost data the projected annual cost of ADR admissions to the NHS in England is £2.21 bn. With 39.4% of these ADRs identified as avoidable or potentially avoidable future efforts should be directed to reduce this burden. Reducing inappropriate polypharmacy should be a major aim for preventing ADRs.

## DECLARATIONS

### Competing interests

The authors have read the BMJ policy on declaration of interests and have nothing to declare.

### Funding statement

MP receives research funding from various organisations including the MRC and NIHR. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis); a PhD studentship jointly funded by EPSRC and Astra Zeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT ([www.ardat.org](http://www.ardat.org)). None of these of funding sources have been used for the current paper.

There were no patient contributors or co-authors in this study.

### Ethics approval

Approval was granted by Liverpool University Hospital Foundation NHS Trust clinical audit and service evaluation department (Project number 7580).

### Data sharing

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis

1  
2  
3 to the BMJ Publishing Group Ltd (“BMJ”), and its Licencees to permit this article (if accepted) to be  
4 published in The BMJ’s editions and any other BMJ products and to exploit all subsidiary rights, as  
5 set out in our licence.  
6  
7

### 8 Contributorship

9  
10  
11 Dr Rostam Osanlou undertook data collection, statistical analysis and wrote the initial draft of the  
12 paper. Dr Lauren Walker was involved in data collection, second reviewer and paper write up.  
13  
14 Professor Dyfrig Hughes undertaking to the cost analysis in this study. Dr Girvan Burnside undertook  
15 statistical analysis of data and contributed to paper write up. Professor Sir Munir Pirmohamed came  
16 up with the idea, and was involved in assessing clinical cases and in reviewing the initial drafts and  
17 final draft of the paper.  
18  
19  
20  
21  
22

### 23 References

- 24  
25  
26 1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for  
27 health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43.  
28 doi: 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]  
29  
30 2. Addressing the global challenge of multimorbidity, The Academy of Medical Sciences [Internet].  
31 Acmedsci.ac.uk. 2020 [cited 15 December 2020]. Available from:  
32 <https://acmedsci.ac.uk/policy/policy-projects/multimorbidity/evidence-submission>.  
33  
34 3. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Curr Biol* 2012;22(17):R741-52. doi:  
35 10.1016/j.cub.2012.07.024 [published Online First: 2012/09/15]  
36  
37 4. Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of  
38 definitions. *BMC Geriatr* 2017;17(1):230. doi: 10.1186/s12877-017-0621-2 [published Online First:  
39 2017/10/12]  
40  
41 5. NHS Business Service Authority, Wessex Academic Health Science Network. (2017) Medicines  
42 Optimisation: Polypharmacy [https://www.nhsbsa.nhs.uk/epact2/epact2-](https://www.nhsbsa.nhs.uk/epact2/epact2-dashboard/specifications/medicinesoptimisation-polypharmacy)  
43 [dashboard/specifications/medicinesoptimisation-polypharmacy](https://www.nhsbsa.nhs.uk/epact2/epact2-dashboard/specifications/medicinesoptimisation-polypharmacy).  
44  
45 6. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-  
46 drug interactions: population database analysis 1995-2010. *BMC Med* 2015;13:74. doi:  
47 10.1186/s12916-015-0322-7 [published Online First: 2015/04/19]  
48  
49 7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a  
50 meta-analysis of prospective studies. *JAMA* 1998;279(15):1200-5. doi: 10.1001/jama.279.15.1200  
51 [published Online First: 1998/04/29]  
52  
53 8. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to  
54 hospital: prospective analysis of 18 820 patients. *BMJ* 2004;329(7456):15-9. doi:  
55 10.1136/bmj.329.7456.15 [published Online First: 2004/07/03]  
56  
57  
58  
59  
60

- 1  
2  
3 9. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a  
4 review of recent observational studies. *Drug Saf* 2015;38(5):437-53. doi: 10.1007/s40264-015-0281-  
5 0 [published Online First: 2015/03/31]  
6
- 7  
8 10. Ayalew MB, Tegegn HG, Abdela OA. Drug Related Hospital Admissions; A Systematic Review of  
9 the Recent Literatures. *Bull Emerg Trauma* 2019;7(4):339-46. doi: 10.29252/beat-070401 [published  
10 Online First: 2019/12/21]  
11
- 12  
13 11. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in  
14 Scotland. *Pharm World Sci* 2008;30(6):854-62. doi: 10.1007/s11096-008-9240-5 [published Online  
15 First: 2008/07/26]  
16
- 17  
18 12. Bednall R, McRobbie D, Hicks A. Identification of medication-related attendances at an A & E  
19 department. *J Clin Pharm Ther* 2003;28(1):41-5. doi: 10.1046/j.0269-4727.2003.00461.x [published  
20 Online First: 2003/02/28]  
21
- 22  
23 13. Bps.ac.uk. 2016. The case for savings in the NHS. [online] Available at:  
24 <[https://www.bps.ac.uk/getmedia/8f24b222-b355-4f4a-8d91-f0a56190381e/The-case-for-savings-  
25 in-the-NHS-December-2016.pdf.aspx?ext=.pdf](https://www.bps.ac.uk/getmedia/8f24b222-b355-4f4a-8d91-f0a56190381e/The-case-for-savings-in-the-NHS-December-2016.pdf.aspx?ext=.pdf)> [Accessed 21 December 2021].  
26
- 27  
28 14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet*  
29 2000;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9 [published Online First: 2000/11/10]  
30
- 31  
32 15. Davies DM, Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM,  
33 ed. Textbook of adverse drug reactions. Oxford: Oxford University Press,1991:18–45  
34
- 35  
36 16. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the  
37 Liverpool adverse drug reaction causality assessment tool. *PLoS One* 2011;6(12):e28096. doi:  
38 10.1371/journal.pone.0028096 [published Online First: 2011/12/24]  
39
- 40  
41 17. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse  
42 drug reactions. *Am J Hosp Pharm* 1992;49(9):2229-32. [published Online First: 1992/09/01]  
43
- 44  
45 18. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. *Ann*  
46 *Pharmacother* 2007;41(4):674-80. doi: 10.1345/aph.1H423 [published Online First: 2007/03/29]  
47
- 48  
49 19. Bracken LE, Nunn AJ, Kirkham JJ, et al. Development of the Liverpool Adverse Drug Reaction  
50 Avoidability Assessment Tool. *PLoS One* 2017;12(1):e0169393. doi: 10.1371/journal.pone.0169393  
51 [published Online First: 2017/01/04]  
52
- 53  
54 20. Joint Formulary Committee (2019) BNF 78: September 2019-March 2020. London:  
55 Pharmaceutical Press.  
56
- 57  
58 21. England, N., 2021. NHS England » National Cost Collection for the NHS. [online] England.nhs.uk.  
59 Available at: <<https://www.england.nhs.uk/national-cost-collection/#ncc1819>> [Accessed 4 January  
60 2021].

- 1  
2  
3 22. Patel PB, Patel TK. Mortality among patients due to adverse drug reactions that occur following  
4 hospitalisation: a meta-analysis. *Eur J Clin Pharmacol* 2019;75(9):1293-307. doi: 10.1007/s00228-  
5 019-02702-4 [published Online First: 2019/06/12]  
6  
7  
8 23. Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse  
9 drug reactions and preventability of adverse drug reactions--a meta-analysis. *PLoS One*  
10 2012;7(3):e33236. doi: 10.1371/journal.pone.0033236 [published Online First: 2012/03/23]  
11  
12 24. Nwadiugwu MC. Frailty and the Risk of Polypharmacy in the Older Person: Enabling and  
13 Preventative Approaches. *Journal of Aging Research* 2020;2020:6759521. doi:  
14 10.1155/2020/6759521  
15  
16 25. Coleman JJ, Pontefract SK. Adverse drug reactions. *Clin Med (Lond)* 2016;16(5):481-85. doi:  
17 10.7861/clinmedicine.16-5-481 [published Online First: 2016/10/05]  
18  
19 26. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious  
20 pneumonia. *Thorax* 2013;68(11):1029-36. doi: 10.1136/thoraxjnl-2012-202872 [published Online  
21 First: 2013/10/17]  
22  
23 27. Chisholm-Burns MA, Spivey CA, Sherwin E, et al. The opioid crisis: Origins, trends, policies, and  
24 the roles of pharmacists. *Am J Health Syst Pharm* 2019;76(7):424-35. doi: 10.1093/ajhp/zxy089  
25 [published Online First: 2019/07/31]  
26  
27 28. Brath H, Mehta N, Savage RD, et al. What Is Known About Preventing, Detecting, and Reversing  
28 Prescribing Cascades: A Scoping Review. *J Am Geriatr Soc* 2018;66(11):2079-85. doi:  
29 10.1111/jgs.15543 [published Online First: 2018/10/20]  
30  
31 29. Piggott KL, Mehta N, Wong CL, et al. Using a clinical process map to identify prescribing cascades  
32 in your patient. *BMJ* 2020;368:m261. doi: 10.1136/bmj.m261 [published Online First: 2020/02/23]  
33  
34 30. Compass. Adverse drug reactions wastes NHS £2BN reveals Compass. Compass; London; 2008.  
35 [Cited in <https://www.theguardian.com/society/2008/apr/03/nhs.drugsandalcohol>]  
36  
37 31. National Institute for Health and Care Excellence. Costing statement: Medicines optimisation.  
38 Implementing the NICE guideline on medicines optimisation (NG5). March 2015.  
39 <https://www.nice.org.uk/guidance/ng5/resources/costing-statement-6916717>  
40  
41 32. Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults  
42 following hospital discharge: a multicentre prospective study in the UK. *Br J Clin Pharmacol*  
43 2018;84(8):1789-97. doi: 10.1111/bcp.13613 [published Online First: 2018/05/24]  
44  
45 33. English indices of deprivation 2019 [Internet]. GOV.UK; 2020 [cited 31 August 2020]. Available  
46 from: <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019>.  
47  
48 34. Newton JN, Briggs AD, Murray CJ, et al. Changes in health in England, with analysis by English  
49 regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease  
50 Study 2013. *Lancet* 2015;386(10010):2257-74. doi: 10.1016/S0140-6736(15)00195-6 [published  
51 Online First: 2015/09/19]  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables

**Table 1 – Drugs implicated in patient episodes with adverse drug reactions\***

Drug class	No of ADRs (%)	Offending drug	ADR
Diuretics	31 (14.2%)	Furosemide (13), pironolactone (8), bumetanide (6), bendroflumethiazide (2), coamilofruse (1), indapamide (1)	Renal impairment (18), electrolyte derangement (12), postural hypotension (1)
Steroid inhaler	27 (12.4%)	Steroid inhaler (27)	Pneumonia (26), Oral Thrush (1)
Anticoagulants	21 (9.6%)	Warfarin (7), apixaban (5), edoxaban (4), rivaroxaban (4), enoxaparin (1)	Minor bleeding (10), anaemia (4), intracranial haemorrhage (4), Gastrointestinal bleed (3)
Proton pump inhibitor	18 (8.3%)	Lansoprazole (9), omeprazole (6), pantoprazole (3)	Hypomagnesaemia (11), hyponatraemia (6), C.Diff (1)
Antiplatelet	16 (7.4%)	Aspirin (13), clopidogrel (3)	Intracranial haemorrhage (5), Gastrointestinal bleed (4), minor bleeding (4), anaemia
Chemotherapy	16 (7.3%)	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Deranged electrolytes (1), Rash (1), Thrombocytopenia (1)
ACE <sup>(1)</sup> -inhibitor / angiotensin receptor blocker	14 (6.4%)	Losartan (4), ramipril (4), irbesartan (3), candesartan (1), lisinopril (1), perindopril (1)	Renal impairment (9), postural hypotension (3), hyperkalaemia (1), renal failure (1)

Antidepressants & Antipsychotics	13 (6.0%)	Mirtazapine (2), sertraline (2), sulpride (2), carbamazepine (1), dosulepin (1), nortriptyline (1), olanzapine (1), risperidone (1)	Confusion (3), hyponatraemia (3), parkinsonism (3), constipation (1), gastrointestinal bleed (1), prolonged QTc <sup>(2)</sup> (1)
Opiates	13 (6.0%)	Codeine (5), morphine sulphate (3), oxycodone (2), tramadol (2), buprenorphine (1)	Constipation (6), confusion (4), respiratory depression (2), hallucinations (1)
Other	49 (22.4%)	Other (49)	Other (49)
<p><sup>(1)</sup> Angiotensin converting enzyme <sup>(2)</sup> Corrected QT interval</p> <p>*In those with multiple ADRs only the most severe ADR was included in this table, as defined by the adapted Hartwig severity scale <sup>(16)</sup>. See supplementary material for full list.</p>			



**Table 2– Deaths directly related to the adverse reaction (Adapted Hartwig class 7b)**

Medication	Number	Cause of death
Chemotherapy	2	Neutropenic sepsis (2)
Aspirin	1	Intracranial haemorrhage
Edoxaban	1	Gastrointestinal bleed

For peer review only

**Table 3 – Characteristics of patients with and without adverse drug reactions**

	ADR <sup>(1)</sup> group	Non ADR group	Total
<b>Number of admissions</b>	218	969	1187
<b>Age</b>			
Mean (s.d.)	73.2 (14.5)	66.7 (19.2)	67.9 (18.6)
<b>Male (%)</b>	106 (48.6%)	455 (47.0%)	561 (47.3%)
<b>Number of medicines</b>			
Mean (s.d.)	10.5 (4.6)	7.8 (5.1)	8.3 (5.1)
<b>Polypharmacy (%)</b>	199 (91.3%)	706 (72.9%)	905 (76.2%)
<b>Number of co-morbidities</b>			
Mean (s.d.)	6.1 (3.0)	5.2 (3.3)	5.4 (3.2)
<b>Multimorbid (%)</b>	99.1%	90.3%	91.9%
<b>Liver impairment * (%)</b>	6.9%	2.8%	3.5%
<b>Renal impairment ** (%)</b>	11.0%	6.8%	7.6%
<sup>(1)</sup> Adverse drug reation			
* Liver impairment defined as Chronic Liver Disease			
** Renal impairment defined as Chronic Kidney Disease stage IV or V			

**Table 4: Logistic regression analysis of patients with and without adverse drug reactions**

	<b>Univariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>	<b>Multivariable odds ratio (95% CI)</b>	<b>p-value (Wald chi-square)</b>
<b>Age</b>	1.02 (1.01, 1.03)	<0.001	1.02 (1.01, 1.03)	<0.001
<b>Sex (Male)</b>	1.07 (0.80, 1.44)	0.659		
<b>Number of medicines</b>	1.11 (1.07, 1.14)	<0.001	1.10 (1.07, 1.13)	<0.001
<b>Number of comorbidities</b>	1.08 (1.04, 1.13)	<0.001		
<b>Liver impairment (CLD)</b>	2.58 (1.35, 4.93)	0.004	3.23 (1.63, 6.40)	<0.001
<b>Renal impairment (CKD stage 4 or 5)</b>	1.69 (1.04, 2.78)	0.036		

## Supplementary material - Full list of Adverse reactions by drug class

Drug Class	Number of associated ADRs	Medications implicated	Adverse reaction
<b>Diuretics</b>	31	Furosemide (13), Spironolactone (8), Bumetanide (6), Bendroflumethiazide (2), Coamilofruse (1), Indapamide (1)	Renal impairment (18), Electrolyte derrangement (12), Postural hypotension (1)
<b>Steroid inhaler</b>	27	Steroid inhaler (27)	CAP (26), Oral Thrush (1)
<b>Anticoagulants</b>	21	Warfarin (7), Apixaban (5), Edoxaban (4), Rivaroxaban (4), Enoxaparin (1)	Minor bleeding (10), Anaemia (4), Intracranial haemmhorage (4), GI bleed (3)
<b>Proton Pump Inhibitor</b>	18	Lansoprazole (9), Omeprazole (6), Pantoprazole (3)	Hypomagnasaemia (11), Hyponatraemia (6), C.Diff (1)
<b>Antiplatelets</b>	16	Aspirin (13), Clopidogrel (3)	Intracranial haemoorrhage (5), GI bleed (4), Minor bleeding (4), Anaemia
<b>Chemotherapy</b>	16	Chemotherapy (16)	Neutropenic Sepsis (8), Sepsis (4), Constipation (1), Derranged electrolytes (1), Rash (1), Thromocytopenia (1)
<b>ACE-I <sup>(1)</sup> /ARB <sup>(2)</sup></b>	14	Losartan (4), Ramipril (4), Irbesartan (3), Candesartan (1), Lisinopril (1), Perindopril (1)	Renal impairment (9), Postural hypotension (3), Hyperkalaemia (1), Renal failure (1)
<b>Antidepressants &amp; antipsychotics</b>	13	Mirtazapine (2), Sertraline (2), Sulpride (2), Carbamazepine (1), Dosulepin (1), Nortriptyline (1), Olanzapine (1), Risperidone (1)	Confusion (3), Hyponatraemia (3), Parkinsonism (3), Constipation (1), GI bleed (1), Prolonged QTc (1)
<b>Opiates</b>	13	Codeine (5), Morphine Sulphate (3), Oxycodone (2), Tramadol (2), Buprenorphine (1)	Constipation (6), Confusion (4), Respiratory Depression (2), Hallucinations (1)
<b>Beta adrenoceptor blockers</b>	9	Bisoprolol (6), Atenolol (1), Nebivolol (1), Propranolol (1)	Bradycardia (5), Postural hypotension (4)
<b>Insulin</b>	7	Insulin (7)	Hypoglycaemia (4), Hypoglycaemic seizures (2)
<b>Calcium Channel Blocker</b>	6	Amlodipine (4), Ivabradine (1), Diltiazem (1)	Postural hypotension (5), Prolonged QTc (1)
<b>Bladder anticholinergics</b>	6	Solifenacin (4), Tolterodine (1), Tropsium (1)	Confusion (4), Constipation (2)
<b>Immunosuppressants</b>	5	MMF (3), Tacrolimus (2)	Sepsis (5)
<b>Antimicrobials</b>	4	Penicillin (2), Aciclovir (1), Azithromicin (1)	Angioedema (1), Rash (1), Renal impairment (1), Prolonged QTc (1)

<b>Oral anti diabetics</b>	4	Gliclazide (2), Empagliflozin (1), Pioglitazone (1)	Hypoglycaemia (2), Heart Failure (1), Urinary Tract infection (1)
<b>Monoclonals</b>	3	Afatanib (1), Pembrolizumab (1), Ruxolitinib (1)	Liver toxicity (1), Pneumonitis (1), Sepsis (1)
<b>Statins</b>	2	Atorvastatin (1), Simvastatin (1)	Myopathy (2)
<b>Levodopa</b>	2	Co-beneldopa (1), Co-careldopa (1)	Postural Hypotension (2)
<b>PTH<sup>(3)</sup> analogues</b>	2	Alfacalcidol (1), Calcitriol (1)	Hypercalcaemia (2)
<b>NSAIDs<sup>(4)</sup></b>	2	Naproxen (2)	ACS (1), GI Bleed (1)
<b>Benzodiazepines</b>	2	Lorazepam (1), Tempazepam (1)	Confusion (2)
<b>Baclofen</b>	1	Baclofen (1)	Constipation (1)
<b>Amitriptyline</b>	1	Amitriptyline (1)	Confusion (1)
<b>Leviteracitem</b>	1	Leviteracitem (1)	Renal impairment (1)
<b>Doxazocin</b>	1	Doxazocin (1)	Postural hypotension (1)
<b>Nefopam</b>	1	Nefopam (1)	Delirium (1)
<b>Quinine</b>	1	Quinine (1)	Prolonged QTc (1)
<b>Lithium</b>	1	Lithium (1)	Lithium Toxicity (1)
<b>Laxatives</b>	1	Laxatives (1)	Diarrhoea (1)
<b>Bisphosphonates</b>	1	Alendronic Acid (1)	Erosive Gastritis (1)
<b>Thyroxine</b>	1	Levothyroxine (1)	Tachyarrhythmia (1)
<b>Zopiclone</b>	1	Zopiclone (1)	Confusion (1)
<b>Phosphodiesterase inhibitor</b>	1	Uniphyllin (1)	Nausea (1)

(1) Angiotensin converting enzyme inhibitor (2) Angiotensin receptor blocker (3) Parathyroid hormone (4) Non steroidal anti inflammatory

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	4
		(c) Explain how missing data were addressed	4
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	4
		(e) Describe any sensitivity analyses	n/a

Continued on next page

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	4
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	16
		(b) Indicate number of participants with missing data for each variable of interest	4
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	n/a
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	n/a
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	n/a
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	16
		(b) Report category boundaries when continuous variables were categorized	16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Table 4

**Discussion**

Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	10

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Additional
---------	----	---	------------

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).